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Folates also known as vitamin B9 are essential substrates for de novo nucleic 
acid synthesis and for many biological methylation processes. As a result, 
folate deficiency is associated with numerous diseases such as fetal neural 
tube defects, cardiovascular diseases, and cancers. High affinity uptake of 
folates requires folate receptors (FRα, β, γ), which are cell surface 
glycoproteins mediating folate intake by endocytosis. FRα is the most 
prevalent isoform of FRs, and its expression is restricted to apical surface of 
epithelial cells in choroid plexus, proximal kidney tubules and placenta. In 
contrast to limited normal tissue distribution, FRα is overexpressed in a 
spectrum of tumors, such as ovarian cancer, endometrial cancer and breast 
cancer. As such, FRα has become the molecular target for the development of 
many cancer therapeutics. Despite intense research on the folate structure-
activity relationship, the molecular basis for the high affinity recognition of 
folates by FRα remains elusive due to the technical difficulties in expression, 
purification, and crystallization of FRα for structural studies. 
Here, we developed a mammalian expression system which yielded correctly 
folded cysteine-rich FRα in sufficient amount for crystallization. By 
combining the treatments of glycosylation inhibitor and enzymatic 
deglycosylation, we obtained homogenous protein which produced crystals 
diffracting to 2.8Å. We solved the crystal structure of FRα-folic acid complex 
which provided the molecular basis for the high affinity binding.   
Folate receptor is a globular protein which consists of six helices, two pairs of 





FRα has a deep binding pocket with one end open, which accommodates folic 
acid with its pteroate moiety buried inside and glutamate group sticking 
outside. The overall structure assumes a hand-like structure. The binding 
pocket is almost perpendicular to the plane formed by helix α1, α2 and α3, 
which is the palm of the hand. Whereas the N-terminal loop,  loops between 
α1-α2, β1-β2 and α3-α4 are the fingers which grab the folic acid in middle.  
The crystal structure also revealed the detailed folic acid binding mechanism 
of FRα. First, the overall shape and charge distribution of FRα ligand binding 
pocket is complementary to folic acid. The basic pteroate head of folic acid is 
buried within the positively charged interior of the pocket, whilst the acidic 
tail of folic acid is stabilized by the negatively charged exterior. Second, the 
parallel side chains of Y85 and W171 stacking the pterin ring in between, 
together with D81, which forms a pair of strong hydrogen bonds with N1 and 
N2 of pterin, anchor folic acid inside the binding pocket. Third, there is an 
extensive network of hydrogen bonds and hydrophobic interactions lining the 
binding pocket. To validate these structural observations, we examined the 
ligand-binding affinities of FRα mutants that have alanine mutations in the key 
folate-contacting residues. Results indicate that the extensive interaction 
network makes FRα–folic acid binding remarkably resistant to single point 
mutations. 
In summary, the FRα–folic acid complex structure illustrates how the receptor 
assumes a deep folate-binding pocket that is formed by conserved residues 
across all receptor subtypes and provides detailed insights into how folic acid 
interacts with its receptors. Together, these observations lay a foundation for 
future FR-targeted anticancer drug development.  
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1.1 Folate  
1.1.1 Introduction of folate  
Folic acid was first discovered in 1931 by Lucy Wills as a critical substance in 
yeast extract against the tropical macrocytic anemia, which was often 
observed during pregnancy in India [1]. Later on, the same substance was 
isolated from spinach leaves and the chemical structure was solved [2, 3]. 
Folic acid is composed of an aromatic pterin ring linked to a para-
aminobenzoic acid which is conjugated to one glutamate residue (Fig.1a). 
Naturally-occurring folate is a mixture of reduced folate polyglutamates, 
differing in the oxidation state of the pterin ring, the character of one-carbon 
substitution at N5 and N10 positions, and the number of glutamate acid 
conjugated. The most important natural folates are illustrated in Figure 1b.  
Human body cannot synthesize folate de novo, thus depends on the dietary 
intake. Leafy vegetable is principle source of folate, which is also where the 
name folate is derived from. In Latin, word "folium" means leaf. Animal liver 
and kidney products and citrus fruit are also good source of folate [4]. 
Natural folate is chemically unstable and subject to oxidative rearrangement 
during harvesting, storage, processing and cooking, which lead to a significant 
loss of biochemical activity.  Hence, the more stable synthetic form, folic acid, 
is manufactured and fortified in grain products and cereals in more than 60 
countries [5].  
Polyglutamyl 5-methyl tetrahydrofolate (5-methyl-THFGlun) is the 





removed in brush border of mucosal cells and is subsequently absorbed in 
jejunum [6]. As a result, the primary form of folate in circulation is 5-methyl 












Figure 1. Chemical structure of folic acid and folate derivatives. a) 
Constitution of folic acid. b) Tetrahydrofolate (THF) and its derivatives due to 








1.1.2 Folate metabolism 
The mammalian folic acid metabolism is a highly complex but crucial process, 
which is also referred to as one-carbon metabolism. The principle role of 
folate coenzymes is to transfer one-carbon units to amino acids, nucleotides, 
and other biomolecules [8].  
Dietary folic acid can be enzymatically reduced to dihydrofolate (DHF) and 
subsequently tetrahydrofolate(THF) by dihydrofolate reductase (DHFR).  
Then THF acquires one-carbon group from several metabolic precursors to 
form functional folates (Fig. 2a). Serine hydroxymethyltransferase (SHMT) 
utilizes serine as carbon source to convert THF to 5,10-methylene THF. Part 
of 5,10-methylene THF can be irreversibly reduced to 5-methyl THF by 
methylene tetrahydrofolate reductase (MTHFR) [9]. Other than that, THF can 
also gain one carbon unit from methionine to make 5-methyl THF, which is a 
reversible process catalyzed by methionine synthase (MS). Finally, THF 
together with formate and ATP are substrates for formate–tetrahydrofolate 
ligase (MTHFD1) to synthesize 10-formal THF, which is another important 
functional folate. 
Figure 2b illustrates the two main functions of folate metabolism: DNA 
synthesis and biological methylations. In DNA synthesis, 5,10-methylene THF 
donates one methyl group to deoxyuridylate to make thymidylate (dTMP), the 
precursor of one of DNA building blocks. This reaction is catalyzed by 
thymidylate synthase (TS). In addition, in de novo synthesis of purine, 
glycinamide ribonucleotide transformylase (GARFT) and aminoimidazole-4- 





carbon group from 10-formyl THF to the purine ring, generating additional 
two DNA building blocks: adenine and guanine. 
In biological methylation reactions, folate metabolism is crucial to maintain 
adequate supply of S-adenosylmethionine (SAM), the activated form of 
methionine and key methyl donor in methylation. SAM participates in more 
than 100 types of methylation reactions, which includes methylation of DNA, 
lipids and proteins. These reactions effectively consume the methyl group in 
methionine, which is replenished by MS using 5-methyl THF as the carbon 
donor [10].  This constant consumption and regeneration process of 



























Figure 2. Metabolism of folates. a) Generation of important THF derivatives. 









1.1.3 Folate transport system 
Human body employs three genetic and functional distinct classes of 
transporters to mediate folate absorption and transportation: proton-coupled 
folate transporter, reduced folate carrier and folate receptors (Fig.3) [11].  
The proton-coupled folate transporter (PCFT) belongs to solute carrier family 
19 (SLC19), and is an anionic exchanger with 12 transmembrane domains 
(TMDs). PCFT contains large intracellular N-terminal, C-terminal loops as 
well as a long cytoplasmic loop connecting TMD6 and TMD7[12]. It is highly 
expressed in the duodenum and facilitates the intake of folate monoglutamate 
into the body. Consistent with its role in intestinal folate absorption, an 
inactivating mutation in PCFT has been demonstrated to be a genetic cause of 
a rare autosomal recessive disorder, namely hereditary folate malabsorption, 
which is a folate deficient syndrome caused by impaired intestinal folate 





exchanger. PCFT operates optimally at pH 5.5, and its 
folate transport activity increases as pH decreases [14]. PCFT expression has 
been found in a wide array of human solid tumor cell lines [15], which is in 
concordance with previous studies that have shown a spectrum of human 
tumor cell lines display a prominent folate transport activity at acidic pH [16].  
Reduced folate carrier (RFC) is ubiquitously expressed in human body. In fact, 
it is the primary route of delivery of folate into systemic tissues. RFC 
transports 5-methylTHF and 5-formylTHF with affinity in 2-7 μM range [17]. 
In addition, it is responsible for cellular uptake of antifolate cancer 





solute carrier family. It consists of 12 TMDs with short hydrophilic N-terminal 
and long hydrophilic C-terminal loops, both residing in the cytoplasm. In 
addition, RFC contains a long cytoplasmic loop connecting TMD6 and TMD7 
[19]. RFC is heavily glycosylated in Asn58, located at the loop between 
TMD1 and TMD2 [20]. RFC is a bidirectional antiporter, which mediates the 
exchange of folate with organic phosphate that is generated and retained in the 
cell from ATP-dependent reactions [21].  
Unlike PCTF and RCF, folate receptors (FRs) are folate binding proteins 
which lack TMDs. There are three subtypes of FRs: -α,-β, and -γ, among 
which,  α and β subtypes are glycophosphatidylinositol (GPI)-anchored cell 
surface proteins, whereas FR-γ is secreted due to lack of GPI signal peptide. 
FRs bind to folic acid with Kd <2nM, which clearly distinguishes FRs from 
RFC and PCFT [22]. FRs will be discussed in detail in a separated section in 








Figure 3. Folate transport system. PCFT is expressed in intestine for 
absorption of food folate. Cellular uptake of folate is through RFC anion 





1.2 Folate deficiency  
Considering the indispensable role of folate in biosynthesis of purine and 
thymidine, folate deficiency will affect the DNA biosynthesis and thereby 
limit cell division. Folate deficiency is most obvious in rapidly proliferating 
cells, such as red blood cells, leading to anaemia; hemopoietic cells of bone 
marrow, resulting in leucopenia and thrombocytopenia; and epithelium cells of 
gastrointestinal tract, causing intestinal malfunction. However, these overt 
folate deficiency associated ailments are rare and largely confined in less 
developed countries. In addition, nutritional deficiency of folate is common in 
people consuming a limited  diet and in pregnant women, especially during 
periods of rapid fetal growth[23].  
Over the past decade, increasing evidence suggest low folate status introduces 
long-term health risks and associates with various disorders, including neural 
tube defect, cardiovascular diseases, as well as cancer. The underlying 
mechanisms will be elaborated in the following section.  
1.2.1 Neural tube defects 
Neural tube defects (NTDs) are one of most common congenital abnormalities, 
affecting approximately one infant per thousand births [24]. NTDs occur 
between gestational weeks two and six and are caused by failure of neural tube 
closure during early embryogenesis. There are several types of NTDs, 
differing in the severity and location of the defect. The most common NTDs 
include anencephaly and spina bifida, which result from the failure of fusion 





The most significant epidemiologic finding relevant to NTDs is the protective 
role of folic acid in reducing the NTDs incidence. It is now agreed that a 
supplement of 400µg folic acid taken near the time of conception will reduce 
the incidence as much as 60%-70% [26].  
Although the molecular mechanism by which folic acid exerts its protective 
role is still unclear, the link between folic acid and NTDs has stimulated a 
number of studies to investigate the genes that are involved in folate 
metabolism and transportation. The major cellular folate entry routes include 
FRs and RFC. The importance of FRα in embryogenesis has been 
demonstrated in FRα knockout mice. These mice are embryonic lethal with 
exencephaly phenotype [27]. Screening of FRα gene pointed out no variant in 
coding region and few single nucleotides polymorphisms (SNPs) associated 
with NTDs [28, 29] . In contrast, one common SNP, 80A>G in RFC has been 
proven to be a risk factor for NTDs [30].  
In addition, a number of candidate genes involved in folate metabolism has 
been identified to be associated with NTDs. MTHFR is one of the most 
intensively studied enzymes. MTHFR reduces 5,10-methylene THF to 5-
methyl THF, the methyl donor for methionine cycle. Thus, MTHFR regulates 
the availability of folate entering methionine cycle. A common SNP in 
MTHFR, 677C>T, resulting in reduced enzyme activity, is associated with 
elevated levels of plasma homocysteine and increased risk of NTDs in many 
studies [31]. Some studies also evaluated whether multivitamin supplement 
would manipulate the risk of homozygous 677T/677T variant genotype toward 
NTDs. For infants with 677T/677T genotype, maternal multivitamin uptake 





[32]. A second mutation in MTHFR gene, 1298A>C, has been found to be 
associated with reduced enzyme activity and increased risk of NTDs with no 
effect on plasma homocysteine level [33].  
Methionine synthase (MS) also known as 5-methylTHF homocysteine 
methyltransferase (MTR), catalyzes the conversion of homocysteine to 
methionine using cobalamin (vitamin B12) as a cofactor. One coding SNP, 
2756A>G, leads to substitution of residue Asp to Gly in the helix involved in 
cofactor binding [34]. However, inconsistent results have been reported about 
its association with an increased NTDs risk[35]. In addition, the oxidation of 
cobalamin cofactor results in inactive MTR, which requires MTR reductase 
(MTRR) to reactivate. 66A>G is a common SNP of MTRR gene and it is 
associated with increased NTDs risk when either cobalamin status is low or 
the infant is MTHFR 677T homozygous [36].    
To sum up, few SNPs identified within candidate genes in folate metabolism 
appear to be causally linked to NTDs. Remarkably, many studies suggest the 
interactions of multiple genes and with environmental factors are critical in 
NTDs etiology. 
Table 1. SNPs in folate-metabolism genes associated with NTDs. 
Gene  Polymorphism  Amino acid change  
RFC  80A>G  R27H  
MTHFR  677C>T  A222V  
1298A>C  E429A  
MS (MTR)  2756A>G  D919G  






1.2.2 Vascular diseases  
Large amount of epidemiological studies have concluded that elevated 
homocysteine (Hcy) level in blood is a strong and independent risk factor for 
vascular diseases in coronary, cerebral and peripheral vessels as well as for 
arterial and venous thromboembolism [37, 38]. A profound reciprocal 
relationship exists between blood Hcy and B vitamins (folate and cobalamin). 
Recycling  of Hcy to methionine requires 5-methyl THF as methyl donor and 
cobalamin as cofactor for methionine synthase. As a result, cobalamin and 
folate deficiency will cause elevated blood Hcy levels. And vitamin B 
supplement has been considered as effective way to normalize blood Hcy level 
and prevent vascular diseases [39]. In addition, mutations in folate dependent 
enzymes, such as 677C>T MTHFR, are also associated with Hcy levels and 
vascular diseases [40, 41], which further supports the role of folate in 
prevention of vascular disease.  
1.2.3 Cancer 
Evidence from epidemiologic studies suggests that folate status modulates the 
risk of cancer in some cancer types. For instance, a cohort study demonstrated 
a protective role of dietary folate against lung cancer in male heavy smokers 
[42]. The most compelling evidence comes from the colorectal cancer. In 
several independent epidemiologic studies, diminished folate status has been 
shown to be associated with an increased risk of colorectal neoplasia [43, 44]. 
In addition, these studies indicated the risk of developing colorectal cancer in 
subjects with highest folate intake is 35% lower compared with the subjects 





out supraphysiologic folate supplement could reduce the risk of colorectal 
neoplasia [47]. 
The mechanism by which folate deficiency modulates carcinogenesis is 
unclear. But there are several plausible ways. Folate is the substrate for de 
novo synthesis of purines and thymidine, and as a result, folate deficiency may 
lead to disruption of DNA integrity and repair, which are pro-carcinogenic 
factors. For example, folate deficiency reduces thymidylate synthesis from 
deoxyuridylate, resulting in increased misincorporation of uracil into DNA. 
Uracil in DNA will be recognized as an error and excised, producing a single-
stranded DNA break. As a result, elevated DNA uracil content and increased 
number of chromosomal breaks have been reported in folate deficient patients 
[48]. 
Folate is critical for the synthesis of SAM, the substrate for DNA methylation. 
DNA methylation is an important determinant in gene expression, 
chromosome structural stability, as well as transcriptional factors binding and 
imprinting. All of these play some roles in cancer development. Interestingly, 
genome hypomethylation has been observed in a spectrum of cancers. And 
long-term folate deficient diet is able to induce genomic hypomethylation in 
human lymphocytic DNA [49]. Induction of site-specific hypomethylation 
may also contribute to the process of carcinogenesis. Folate depletion has been 
shown to induce hypomethylation of p53 tumor suppressor gene coding region, 
which coincides with the region that is mutated most commonly in human 







In 1947, illuminated by the discovery that administration of folic acid 
worsened leukemia, Sidney Farber showed  aminopterin, a folic acid 
antagonist could induce remission in acute lymphoblastic leukemia [51].  
Aminopterin, later replaced by a more potent folic acid analogue, methotrexate 
(MTX), is the first rationally designed anticancer drug, and Sidney Farber is 
regarded as the father of modern chemotherapy. 
Decades later, a large group of folate analogues were developed, which are 
collectively called as antifolate, as they act by impairing folate function. 
Considering the vital role of folate in de novo synthesis of nucleotides,  
antifolate has been used in the treatment of a number of carcinomas. In 
addition, antifolate is also used in autoimmune disease treatment, such as, 
rheumatoid arthritis, psoriasis and Crohn's disease [52]. In this section, I will 
discuss the molecular targets of antifolates, their uptake routes, clinical use 
and mechanisms by which they acquire drug resistance.  
DHFR inhibitors: Although introduced in clinic since 1948, it took two to 
three decades to find out the molecular target and inhibition mechanism of 
MTX. MTX is a potent DHFR inhibitor with Ki of 5pM [53]. Substrate for 
DHFR is DHF, the byproduct of TS activity. Compared with TS, DHFR has a 
very high activity, and as a result, a small fraction of DHFR activity is enough 
to maintain cellular needs for THF. As such, in order to achieve a complete 
inhibition of DHFR, much higher MTX concentration compared to Ki is 
required, i.e. >1µM [54].  Polyglutamylation is important for antifolate 





bioactivity as its original form but resist being exported. MTX 
polyglutamylation makes MTX a potent inhibitor of TS and AICARFT 
without affecting its inhibition on DHFR [55]. MTX is now routinely used in 
clinic for treatment of cancers, autoimmune disease, ectopic pregnancy and for 
induction of medical abortion [56]. MTX is transported mainly by RFC and 
also by PCFT with comparable affinity (Km=2µM at pH 5.5)[13]. Impaired 
RFC transport activity has been found to result in MTX resistance [57].  
Pralatrexate is another DHFR inhibitor which was designed to improve the 
cytotoxicity of MTX. The modification in N
10
 position enhances its uptake by 
RFC and polyglutamylation prolongs the cellular retention [58]. Moreover, 
pralatrexate displays better in vitro and in vivo antitumor efficacy [59]. It has 
successfully passed phase I and II clinical trials in non-small cell lung cancer 
(NSCLC) and was granted an accelerated approval by FDA for treatment of 
relapsed or refractory peripheral T-cell lymphoma (PTCL) [60] [61].  
Trimetrexate (TMQ) is another modification of MTX to overcome its 
resistance. The glutamate residue in MTX is replaced by a hydrophobic 
trimethoxy group, so that TMQ is a lipophilic antifolate and enters cell by 
passive diffusion [62]. As a result, cells resistant to MTX due to impaired RFC 
activity are still sensitive to TMQ. Furthermore, lack of glutamate moiety 
renders TMQ a superior antifolate when antifolate resistance comes from loss 
of function of folylpolyglutamate synthase (FPGS) [63]. Resistance to TMQ 
occurs due to DHFR and ABCB1 gene amplification. ABCB1 gene codes for 
a transporter belonging to multidrug resistance protein family which is 





phase II clinical testing for the anticancer treatment, however, it showed no 
better overall activity compared with existing treatment [64]. 
GARFT inhibitor: Lometrexol is the first GARFT inhibitor to be synthesized. 
It is a potent and specific inhibitor for GARFT, which inhibits the de novo 
purine synthesis [65]. Lometrexol uptake is mediated by RFC and FR [66]. Its 
cytotoxicity is highly dependent on polyglutamylation, so decreased FPGS 
activity is considered as the major mechanism of resistance [67]. Clinical 
studies revealed severe and cumulative anti-proliferative toxicities, especially 
thrombocytopenia and mucositis. Because of these side effects, lometrexol is 
not developed for anticancer treatment [68].   
A second generation of GARFT inhibitor was synthesized  based on the 
studies of lometrexol. AG2034 was designed using the knowledge of crystal 
structure of E.coli GARFT. AG2034 is a potent GARFT inhibitor and a 
specific substrate of FPGS. Importantly, it binds to FR with high affinity [69]. 
AG2034 displayed antitumor activity against a spectrum of cancers both in 
vitro and in vivo [70]. However, like lometrexol, the dose-limiting toxicities 
prevented its further development [71].  
TS inhibitors: Raltitrexed is a potent TS inhibitor and transported into cell 
through RFC and FR [72]. Polyglutamylation increases the potency of 
raltitrexed by 100 fold. Raltitrexed was approved for treatment of advanced 
colorectal cancer and is under clinical trial III in combination with cisplatin to 
treat malignant pleural mesothelioma (MPM) [73, 74].  
Pemetrexed was first synthesized based on lometrexol, but it turned out to be a 





by RFC and especially PCFT. It undergoes rapid and efficient 
polyglutamylation[76]. Compared to MTX, pemetrexed is a superior FPGS 
substrate with rapid cellular accumulation. Besides, polyglutamylation 
increases pemetrexed's  inhibition potency toward TS by eighty four fold. 
Pemetrexed polyglutamates also exhibit GARFT and AICARFT inhibitory 
activity [77]. Hence, pemetrexed is also called "multitargeted antifolate". 
Pemetrexed has been approved by FDA for treatment of MPM and NSCLC, in 
combination of cisplatin [78].  
Nolatrexed is a TS inhibitor designed based on the crystal structure of TS. 
Similar to TMQ, nolatrexed is a nonclassical lipophilic antifolate which enters 
cell by passive diffusion [79]. Resistance to nolatrexed is acquired by TS 
amplification and point mutations decreasing its binding to the drug. Phase III 
trials comparing nolatrexed with doxorubicin for treatment of advanced 
hepatocellular carcinoma (HCC) were conducted, but unfortunately, no better 
survival benefit has been observed [80].  
This section briefly reviewed the important antifolates targeting at key folate-
dependent enzymes including DHFR, GARFT and TS. Table 2 summarizes 
their uptake routes and clinical use. The development of new generation of 






Table 2. Summary of antifolates.  
Name  Target  Transport 
system  
PolyGlu- Clinical Use  




Pralatrexate  DHFR  RFC  Yes   PTCL 
Trimetrexate  DHFR  Passive 
diffusion  
No  No  
Lometrexol  GARFT  RFC /FRα  Yes  No  
AG2034  GARFT RFC /FRα  Yes  No  






PCFT/RFC  Yes  MPM and 
NSCLC 
Nolatrexed  TS  Passive 
diffusion  








1.4 Folate receptors 
1.4.1 Expression,  localization and function of folate receptors 
Folate binding proteins were first identified in human milk [82], serum and 
placenta [83] in 1980s. FR-  is the most widely expressed isoform. 
Immunohistochemical studies revealed its expression in epithelial cells of 
choroid plexus, placenta, proximal kidney tubules, female reproductive tracts, 
breast and salivary glands [84].  On the contrary, FR-β was found to be 
expressed in myelomonocytic lineage and placenta. Interestingly, FR-β 
expressed in normal mature hematopoietic cells are unable to bind to folate in 
contrast to those expressed in the placenta [85]. FR-γ is a constitutively 
secreted protein and has been detected in normal and leukemic hematopoietic 
cells [86].  
FRα and β are GPI anchored cell surface proteins. They mediate the uptake of 
folate through endocytosis. After formation of endosome, the acidic 
environment releases the folate from the receptors, and PCFT co-expressed 
with folate receptors transport folate into the cytoplasm [87] .    
FRα is shown to be highly clustered on the cell surface and associated with 
uncoated membrane invagination rather than clathrin-coated pits by 
immunocytochemistry study [88]. In addition, the receptors are localized in 
membrane domains enriched in cholesterol and sphingolipids [89]. Depletion 
of cholesterol or sphingolipids inhibits the receptor clustering and folate intake 
[90]. These results suggested that folate receptor-mediated folate intake may 
be through caveolae-dependent potocytosis. However, folate receptors were 





addition, electron microscopy study has shown that in steady-state FR is not 
significantly co-localized with caveolin [91]. Hence, folate receptors seem to 
be localized in lipid raft rich in cholesterols and sphingolipids but not caveolae.  
1.4.2 Physiological roles of folate receptors 
At physiological level of folate intake,  little or none folate is lost in the urine 
due to the effective reabsorption in kidney[92]. FRα is highly expressed at the 
apical membrane of luminal brush border in proximal tubules. FRα binds to  
urine folate tightly and internalizes it. After released in cytoplasm, folate is 
exported into blood stream by RFC located at basolateral membrane [93, 94]. 
Transcytosis has been reported as another way for FR-mediated folate 
reabsorption, in which the intact vesicle formed at apical membrane transits to 
the basolateral membrane and discharges the folate into peritubular space [95].  
FRs are not expressed in blood-brain barrier, where the delivery of folate is 
mainly mediated by RFC[96]. In contrast, FRα is expressed in choroid plexus 
and represents the active transport of folate into cerebrospinal fluid (CSF) [97]. 
The normal CSF: blood folate ratio is around 3:1[98]. Patients with auto-
antibodies blocking FRs develop cerebral folate deficiency, which further 
supports the role of FR in folate uptake in the brain [99].  
Rapidly dividing and developing cells have a high folate demand, thus folate 
is particularly essential during pregnancy for fetal development.  Placenta is 
the main link between mother and fetus. It is responsible for the maternal-to-
fetal transfer of nutrients. FRα, FRβ, RFC and PCFT are all found in placenta.  
The importance of FRs in placental folate transport is demonstrated by several 





inhibit maternal to fetal transport of 
3
[H] labelled folate in guinea pig [100]. 
Considering only FRs can bind to folic acid, the maternal-to-fetal transfer of 
folate is likely dependent on FRs. In addition, bafilomycin A specifically  
inhibits the endocytic pathway by blocking proton transport. It can prevent the 
folic acid transport into tumor cells of trophoblastic origin, which further 
supports the role of FRs in placental folate transport [101].   
1.4.3 Implication of folate receptors in human diseases 
Cancer: Although FR  has very limited normal tissue distribution, it is 
overexpressed in various malignant tumors and cancer cell lines [102]. A 
quantitative radio ligand binding assay showed that nonmucinous epithelial 
ovarian cancer cells express highest level of functional FRα, followed by 
kidney, endometrial, lung and breast carcinoma [103]. In addition, FRα 
expression level is positively correlated with tumor stage and grade. Toffoli et 
al. showed that FRα level is a predictor of response to chemotherapy and 
survival rate in the epithelial ovarian cancer patients who failed the primary 
surgery [104]. The similar result was reported by Hartmann LC et al. in breast 
cancer, where higher FRα expression is associated with poorer outcome [105]. 
Similarly, FRβ is also found in several cancers. FRβ is consistently expressed 
in chronic myeloid leukemia [106] and 70% of acute myeloid leukemia [107]. 
How FRs mediate tumor development and progression still remains unknown. 
One possible explanation is that FRs may facilitate tumor cell growth and 
division by enhancing folate intake. Early in vitro studies showed that human 
KB cells grown in folate limited media had elevated FR  both in mRNA and 





grow in folate-deficient environment [109]. These results support the 
hypothesis that FRα confers a growth advantage to tumor by modulating its 
folate uptake. On the other hand, Bagnoli M et al. reported that overexpression 
of FR  in ovarian cancer cells is linked to down regulation of caveolin-1, a 
tumor suppressor modulating many cell signalling proteins. These results 
implied the involvement of FR  in cell signalling pathway [110]. Clearly, 
more clinical and molecular studies are needed to understand the role of FRα 
in cancer etiology and development.  
Rheumatoid Arthritis:  Rheumatoid arthritis (RA) is an autoimmune disease 
characterized by destructive inflammation of joints, which manifests to 
damage of cartilage, bone and muscle[111]. Activated macrophages are the 
key cells to cause tissue destruction by secreting multiple proinflammatory 
substances, including cytokines, chemokines, prostaglandins and reactive 
oxygen species[112]. Although FRβ expressed on the monocytic and 
myelocytic lineages of normal hematopoietic cells is functionally inactive, the 
functional FRβ has been discovered in activated synovial macrophages, taken 
from RA patients[113]. Macrophage activation is a complex process 
determined by the cytokine microenvironment. Depending on the stimulus, 
activated macrophage can be divided into two groups. M1 macrophage is 
derived from granulocyte macrophage colony-stimulating factor (GM-CSF) 
induced differentiation and potentiates Th1 responses, whereas M2 
macrophage is derived from M-CSF stimulation and secretes IL-10 in 
response to pathogens [114].   Functional FRβ is specifically expressed by M2 
macrophages, which constitute synovial macrophages in RA as well as tumor-





anti-RA drug development,  which will be discussed in detail in the next 
section. 
 





1.5 Current drugs targeting folate receptors  
1.5.1 FRα- antibody 
As discussed in the last section, expression of FRα is restricted in normal 
tissues, but highly upregulated in ovarian cancer. In addition, FRα expression 
level is positively correlated with tumor grade, but negatively correlated with 
prognosis.  Considering its putative role in cancer development, a number of 
monoclonal anti-FRα antibodies have been developed. Farletuzumab 
(MORAb-003) was synthesized by Morphotek Inc. and has been tested in 
preclinical and clinical trials. FRα has been previously shown to provide 
cancer cells the ability to grow in folate-deficient condition. Notably, 
Farletuzumab has been demonstrated to inhibit this FRα-dependent cell 
growth. In addition, Farletuzumab elicited antibody-dependent cellular 
cytotoxicity and complement-dependent cytotoxicity in human ovarian cancer 
cell lines and restricted the growth of human ovarian tumor xenografts in mice 
model with a favorable toxicity profile [116].  
These excellent preclinical results have pushed Farletuzumab into clinical 
studies. Phase I clinical study administered Farletuzumab intravenously to 25 
heavily pretreated ovarian cancer patients. Results showed Farletuzumab was 
well tolerated at all doses tested, and no dose-limiting toxicity was 
encountered [117]. After that, a phase II clinical study was launched to 
evaluate the clinical activity of farletuzumab alone and in combination with 
current chemotherapy agents, carboplatin and taxane, in women with first-





combined with carboplatin and taxane enhanced the response rate and duration 
of response without additive toxicity. A phase III study is ongoing [118].  
1.5.2 Novel antifolates 
Classic antifolate has been reviewed in previous section. These antifolates 
selectively target purine and thymidine synthesis pathway, which in turn 
inhibit tumor cell growth. However, since the majority of classic antifolates is 
taken into cell through ubiquitously expressed RFC, these antifolates posses 
limited selectivity for tumor cells over normal proliferative tissues, such as 
bone marrow, gastrointestinal mucosa, skin and hair [81]. As such, novel 
antifolate which has high affinity to restrictedly expressed FRs is desired.  
BGC945 is a good example of novel FRα-targeted antifolate. BGC945 is a 
non-polyglutamatable TS inhibitor with some structural similarity to antifolate 
plevitrexed. Remarkably, affinity of  BCG945 to FRα is 70% that of folic acid. 
In vitro study has demonstrated its selectivity toward FRα-positive cancer cell 
lines, whereas in vivo, it inhibited the growth of FRα-positive tumor 
xenografts [119]. Phase I clinical trial was initiated by Onyx Pharmaceuticals 
in 2009 to evaluate its safety and pharmacokinetics.  
A research group from Wayne State University synthesized and identified a 
series of novel antifolates targeting FRα recently. They are GARFT inhibitors, 
which prevent the growth of  cells expressing FRs, but not cells expressing 
RFC or PCFT [120]. More preclinical studies are needed to further 
characterize these novel antifolates.  





Considering the high tumor-to-normal expression ratio of FRs, the 
inaccessibility of FRs expressed in normal tissue, and the internalization of the 
ligand after binding to the receptor, FR-mediated drug delivery has been 
exploited as a "Trojan horse" to achieve better tumor selectivity (Fig.5). This 
has led to a wide variety of molecules being attached to folic acid, ranging 
from small molecule drugs to DNA-containing formulations, and many of 
them have generated promising results [121] .  
Folate-small molecular weight therapeutic conjugates: The first folate-targeted 
drug tested in human is 
111
In-DTPA-folate, a radiopharmaceutical attached to 
folate. As expected, this conjugate preserved the high binding affinity to FR 
(~1nM affinity) and localized specifically to cancer cells and kidneys in 
cancer patients [122]. Remarkably, kidney FRs are limited to the apical 
surface of proximal tubules and transcytose folate across kidney epitheliums. 
As a result, no kidney toxicity has ever been observed in any folate-conjugates 
treatment [123]. Inspired by the 
111
In-DTPA-folate trial, cytotoxic 
chemotherapeutics were conjugated to folic acid in order to improve the tumor 
cell selectivity and reduce toxicity. A good example is vintafolide (EC145), a 
folate conjugate of desacetylvinblastine hydrazine (DAVLBH), which is a 
derivative of natural product, vinblastine. The unconjugated DAVLBH is a 
highly toxic anti-microtubule drug. In contrast, vintafolide is well tolerated 
and able to eliminate the FR-positive tumor in animal models [124]. 
Vintafolide has performed well in clinical trials I and II. Clinical trial III is 
ongoing for treatment of both ovarian and lung cancer. There are three 
additional folate-drug conjugates in clinical trials, which share similar 





reduced by the conjugated counterpart, hence improving the safety profile. 
Next, the drug is conjugated to folic acid via the disulfide bond. This 
facilitates the release of the drug in intact form in the reduced endosome. 
Lastly, the drug used are hydrophobic thus allowing them to diffuse out of the 
endosome [123].  





Tc-folate conjugate (EC20) was developed, which has shorter 
radioactive half-life and preferred pathway of decay [125]. EC20 was tested 
clinically for cancer patients imaging and showed high FR-positive tumor 
selectivity and rapid normal cell clearance [126]. More exciting result came 
from the intraoperative fluorescence imaging. The fluorescein isothiocyanate 
(FITC) was attached to folate and given to ovarian cancer patients 
intravenously. The real-time visualization of tumor tissue during surgery 
resulted in improved intraoperative staging and more radical debulking [127].  
Folate-macromolecular agent conjugates: Protein toxins, gene therapy vectors, 
liposome-encapsulated drugs are attractive anticancer treatments. Compared 
with traditional chemotherapeutics, these macromolecular agents may have 
enhanced potency, prolonged delivery and other advantages. To enhance the 
tumor targeting and delivery of these macromolecular agents, their folate 
conjugates were developed and tested. For example, folate-coated liposome-
entrapped doxorubicin was developed in 1995, which displayed higher cellular 
uptake and cytotoxicity in vitro [128]. It targeted at FR-positive cell better 
than the uncoated liposome as well as the free drug. In addition, folate coated 
liposomal doxorubicin presented improved therapeutic activity in lymphoma 







Figure 5. Folate-conjugation system. Different molecules can be attached to 
folic acid to generate a "Trojan Horse" to achieve FRs-targeted tumor cell 





1.6 Aims and significance of the study 
The cancer-specific high expression of FRα makes it a very promising 
anticancer drug target, which has been exploited by administration of anti-FRα 
antibodies, high affinity antifolates and folate-conjugated drugs. 
Pharmaceutical importance of FRα has provided a major push for its structural 
study. Although pursued over many decades, FRα structure has never been 
solved due to technical difficulties in purifying soluble and functional proteins 
and obtaining diffracting crystals. FRα is a cysteine rich protein containing 
putative eight disulfide bonds, which makes it extremely difficult to express in 
bacterial expression system [130]. Moreover, mature FRα contains three 
heterogeneous N-linked carbohydrates, which hampers the formation of well-
diffracting crystals [131].  
Hence, this study aims to address the following issues: 
1) To develop a method which leads to successful expression, purification and 
crystallization of functional FRα. This was achieved by systematic screening 
and optimization of current expression systems and deglycosylation methods. 
2) To solve the crystal structure of FRα-folic acid complex. We collected 
multiple datasets in synchrotron and combined different strategies for phase 
determination. 
3) To identify the binding mechanism of FRα. We elucidated and confirmed 
the interaction network between folic acid and the folate receptor ligand-






This long awaited crystal structure of FRα bound to folic acid will be 
extremely important and useful for folate research. This structure not only 
helps to rationalize previous structure-activity relationship studies of folate 
derivatives, but also provides a structural foundation for the future 
development of more specific FRα-targeting drugs and folate-conjugated 
compounds for therapeutic applications. 







MATERIALS AND METHODS 
  




2.1 Plasmid construction 
cDNAs of human FRα, FRβ and FRs from pig (Sus), cow (Bos), Xenopus 
(Xen) and salmon (Salmo) were obtained from Genewiz, Inc and cloned into 
various expression vectors. DNA sequences coding for putative secretion and 
GPI anchor signal peptides were excluded in the plasmid constructs (Fig.6a).  
For bacterial expression system, FRs were cloned into pET24a vector 
(Novagen) with H6GST tag at N terminus, into pSUMO vector (LifeSensors) 
with H6SUMO tag at N terminus and into pETDuet1 (Novagen) vector with 
H6MBP tag at N terminus. A thrombin protease site was constructed between 
each tag and protein of interest. In addition,  MBP-FR fusion construct was 
made. MBP followed by a six-residue linker (NAAAEF) was fused to the N 
terminus of protein and cloned into the multiple cloning site-1 (MCS-1) of 
pETDuet1 vector. Dsbc gene coding for E.coli disulfide bond isomerase was 
cloned into MCS-2 site which will be co-expressed with the MBP fusion 
protein.  
For transient mammalian cell expression, FRs were cloned to pCZ3 vectors 
which was constructed and optimized by prior lab members. H6MBP tag was 
at N terminus or at both N and C terminus of protein and their expression were 
under control of tetracycline response element (TRE). For stable cell 
expression, FRs were cloned to vector pcDNA6 with a murine Igk leader 
sequence at the N terminus, FcH6 (fragment crystallizable region of antibody) 
tag at C terminus, and a thrombin cleavage site between FRs and Fc (Fig.6b). 




Cloning strategies were partly aided by the use of Clone Manager Professional 
ver.9. All the constructed plasmids were verified by DNA sequencing 
















Figure 6. Schematic view of human FRα gene and pCDNA6 construct. a) 
FRα contains a secretion signal peptide (aa1-22) at N terminus and a GPI 
anchor signal peptide (aa235-257) at C terminus.  GPI anchor is attached to 
residue S234. FRα has three glycosylation sites N69, N161 and N201. b) FRα 
(aa23-234) was cloned into pCDNA6 vector with a murine Igk leader 
sequence at the N terminus, FcH6 tag at C terminus, and a thrombin cleavage 
site between FRs and Fc. 
2.2 Cell culture  
For transient cell expression, a previously established suspension cell line, 
FTP7, derived from HEK293 cells (Human Embryonic Kidney 293 cells) was 
a) 
b) 




used. Cells were grown in chemical defined media (CDM, Thermo Scientific) 
supplemented with 5% fetal bovine serum (FBS), and maintained in shake 
flask on  shaker (120rpm) in the incubator at 37°C in 5% CO2. For stable cell 
culture, HEK293 cells were grown in DMEM (Invitrogen) with 5% FBS at 
37°C in 5% CO2.  
2.3 Stable cell selection 
HEK293 cells were transfected with pCDNA6-Ig-FR-Thrombin site-FcH6 and 
selected using 10 mg/ml blasticidin (Invitrogen). Single colonies were grown 
in 24-well plates. Cell media from survival clones was tested for expression of 
protein by biolayer interferometry using an Octet Red instrument (ForteBio). 
Six stable clones were picked up and their expressions were confirmed at each 










Figure 7. Flowchart of stable cell line selection.  




2.4 Protein expression and purification 
2.4.1 Small scale purification of recombinant proteins 
H6GST-, H6SUMO- and H6MBP-tagged recombinant proteins were 
expressed in BL21(DE3) E.coli cells after transformation of expression 
plasmids. 50 ml bacterial culture were grown at 24 °C and shaked at 160 rpm. 
Once cell culture reached the density of OD600~1.0, they were induced with 
0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and grown at 16 °C for 
16 hrs. 1µM folic acid was added after induction. Cells were harvested by 
centrifugation and resuspended in 2 ml of buffer A (25 mM Tris pH 8.0, 150 
mM NaCl, 25 mM imidzole, 10 % glycerol and 1µM folic acid). Cells were 
lysed using FastPrep-24 (MP Biochemicals) over 3 cycles of 20 s 
homogenization at speed 6 with 1 min rest in between each cycle. Cell lysate 
was centrifuged and the supernatants were incubated with Ni-NTA agarose 
beads (Qiagen) at 4 °C for 1 hr with rotation. Proteins bound to the beads were 
spun down and washed with 300 µl of buffer A for 3 times. After that, the 
protein was eluted with 200 µl of buffer B (25 mM Tris pH 8.0, 150 mM NaCl, 
500 mM imidzole, 10 % glycerol and 1 µM folic acid). Final protein 
concentrations were measured by standard Bradford assay and analysed by 
SDS-PAGE. 
FR-FcH6 proteins were expressed in HEK293 cells in 10 cm plate after 
transfection of expression plasmids. Cell media was supplemented with 100 
µM of folic acid and collected 3 days after transfection. Conditioned media 
was dialysed against 1 L buffer C (25 mM Tris pH 8.0, 150 mM NaCl, 1 µM 
folic acid) at 4 °C overnight. Dialysed media was purified using 5 ml Ni-NTA 




column (GE Healthcare). The column was washed with 100 ml buffer A and 
eluted with buffer B.  
2.4.2 Large scale purification of recombinant proteins  
H6GST- FR and H6MBP-FR fusion protein were expressed in BL21(DE3) 
and Rosetta-gami E.coli cells (Novagen) respectively after transformation. 6 L 
of bacterial culture were grown at 24 °C and shaked at 160 rpm. Once cell 
culture reached the density of OD600~1.0, they were induced with 0.1 mM 
IPTG and grown at 16 °C for 16 hrs. 1 µM folic acid was added after 
induction. Cells were harvested by centrifugation and resuspended in 100 ml 
of buffer A. After that, cells were lysed by passing through a French press 
with pressure set at 1000 Pa for 5 minutes. Cell lysates were centrifuged at 
18,000 rpm for 30 mins and the supernatant was loaded on a 5 ml Ni-NTA HP 
column. The column was washed with 100 ml of 5% buffer B and eluted with 
25 ml of 50% buffer B first, followed by 25 ml of 100% buffer B. The peak 
fractions were pooled and concentrated to 10 ml before loading to HiLoad 
26/60 Superdex 200 gel filtration column (GE healthcare) in buffer D (25 mM 
Tris pH 8.0, 200 mM ammonium acetate, 1 mM dithiotreitol (DTT) ,1 mM 
EDTA and 1 µM folic acid).  
MBP-FR-MBP protein was expressed in FTP7 cells. Cells were transfected 
with expression plasmid at density of 2×10
6 
cells/ml, and induced with 1 
µg/ml doxycycline (Dox) at a density of 4×10
6 
cells/ml. Three days after 
induction, 500 ml of conditioned cell media was harvested and concentrated to 
100 ml. Concentrated cell media was dialysed against 2 L of buffer C and 
incubated with 20 ml of amylose resin (New England Biolabs) at 4 °C 




overnight with rotation. Protein bound with resin was washed three times with 
100 ml of buffer E (25 mM Tris pH 8.0, 150 mM NaCl, 10% glycerol and 1 
µM folic acid) and eluted with 20 ml of buffer F (25 mM Tris pH 8.0, 150 mM 
NaCl, 10 mM maltose, 10% glycerol and 1 µM folic acid). Protein was 
concentrated to 2 ml and loaded onto HiLoad 16/600 Superdex 200 gel 
filtration column (GE healthcare) in buffer D.  
FR-FcH6 protein was expressed in HEK293 stable clone maintained in 500 ml 
of DMEM supplement with 5% FBS, 20 mM HEPES, 5 μM kifunensine, and 
200 μM folic acid in 1 L roller bottles at 37 °C.  2 L of conditioned media was 
collected and concentrated to 400 ml and dialyzed against buffer C at 4°C 
overnight before loading on a 50 ml Ni-chelating Sepharose column (GE 
Healthcare).  The column was washed with 300 ml of buffer A and eluted with 
50 ml of 50% buffer B.  The peak fractions were pooled and subjected to 
thrombin digestion at a 1:1000 mass ratio while dialyzing against buffer C at 4° 
C overnight to remove imidazole.  The digestion product was loaded on a 5 ml 
Ni-NTA column to remove the FcH6 tag.  The flow through was collected and 
adjusted to pH 5.6 before adding Endoglycosidase H (Endo H, New England 
Biolabs) for deglycosylation.  Deglycosylated protein was finally separated by 


























Figure 8. Flowchart of purification processes of deglycosylated FRα 
through established stable clone. 
 
2.5 Protein Crystallization and data collection 
Purified FRα protein in buffer D was concentrated to about 7 mg/ml before 
setting up crystallization trials using the Phoenix crystallization robot (Art 
Robbin Instruments) at 20 °C.  Commercial screens (Hampton Research) were 
used in high throughput initial screening. Sitting drop was set up in 96-well 
intelli-plates (Rigaku) with a mixture of 0.2 µl protein and 0.2 µl 
crystallization condition solution sitting in a 75 µl reservoir solution. Once 
crystals appeared in the initial screen, optimization trays were set up manually 
using the hanging drop method at 20 °C. 1 µl of protein was used in each drop 




to set up the screen in 24-well VDX plates (Hampton Research), varying the 
buffer pH, concentrations of salts and precipitants, as well as the volume ratio 
of protein to condition solution.  Needle-shaped crystals were obtained, which 
diffracted X-ray to about 9-10 Å.  To reduce glycosylation, FRα protein was 
expressed in the presence of 5 µM kifunensine (GlycoSyn) [132].  The 
purified FRα protein was treated with Endo H to remove glycosylation.  After 
deglycosylation, crystals were grown at 20 °C in hanging drops containing 1.5 
μl of the purified protein and 1 μl of well solution [0.1 M MES, pH 6.5, 12% 
(v/v) PEG 2000 and 0.15 M potassium sodium tartrate].  Crystals appeared 
within 5-6 days and grew to a dimension of ~250 μm in length with a 
hexagonal shape by day 14.   
Crystals were transferred to well solution with 20% (v/v) ethylene glycol as a 
cryoprotectant before flash freezing in liquid nitrogen. Data collection was 
performed at sector 21-ID-D(LS-CAT) of the APS synchrotron using single 
native crystals and the diffraction data were processed with HKL2000 [133]. 
According to Matthew’s coefficient calculation, the crystals have an unusually 
large unit cell with an estimate of 8–10 molecules per asymmetric unit. Initial 
structure determination by molecular replacement using riboflavin-binding 
protein (which shares 22% sequence identity with FRα) as a search model 
failed to yield any correct solution. To solve the phase problem, a heavy-atom 
derivative was prepared by soaking the native FRα crystals with a Pt salt 
before data collection. Also, six data sets of native FRα were collected at a 
wavelength of 1.77 Å to measure the S anomalous signal to aid in structure 
determination.  
 




2.6 Structure determination (performed by Dr. Jiyuan Ke)  
Six S anomalous data sets were processed using XDS[134], combined using 
Pointless, and merged using Scala of the CCP4 suite [135] as previously 
described to increase the S anomalous signal and the data redundancy [136]. 
Initial phases were established by using the SHELX program[137] with Pt-
soaked derivative data and native data. Fifteen Pt atoms were found by 
SHELXD with a CC/CCweak score of 31.4/17.1 (CC is the correlation 
coefficient between Ecalc and Eobs for all data and CCweak is the correlation 
coefficient for 30% of reflections that were not used during the dual-space 
refinement). Subsequent phasing using SHELXE generated a contrast score of 
0.8 and connectivity of 0.79 for the correct hand solution. Density 
modification for the initial electron density map was performed using DM 
[138]. A crude model was built automatically using the CCP4 program 
buccaneer and improved by manual building using Coot[139]. Phases were 
further improved by using the S anomalous data and a total of 29 S atoms 
were found based on the anomalous difference Fourier using the Phenix 
program[140]. The initial FRα model was manually adjusted on the basis of 
the electron density map using the riboflavin-binding protein structure as a 
reference and the improved model allowed accurate location of eight 
molecules in one asymmetric unit by molecular replacement. The models were 
refined against the native data with eight-fold non-crystallographic symmetry 
restraints using the Refmac program of CCP4[141]. The densities for folic 
acid became clear after several rounds of model adjustments and refinements 
and eight molecules of folate were built into the model. The final model was 
refined to an R factor of 0.206 and an Rfree factor of 0.256. The 




Ramachandran statistics are 87% in the favoured regions, 12.5% in additional 
allowed regions and 0.5% in generously allowed regions. 
2.7 Mutagenesis 
Primers for site-directed mutagenesis were designed using QuickChange 
primer design program (Agilent Technologies). First round of PCR was set up 
in a 25 µl mixture consisting of 1x Phusion high fidelity buffer, 0.5 unit of 
Phusion high fidelity DNA polymerase, 25ng plasmid template, 10µM 
forward/reverse primer and 10mM dNTP. Forward and reverse primer were 
used in separate reactions to prevent annealing to each other. The reaction was 
performed with following steps: denaturation at 98 °C for 30 s, 5 cycles of 
denaturation, annealing and extension at 98 °C for 10 s, 56 °C for 30 s and 
72 °C for 2 mins respectively, followed by final 5 mins of extension at 72 °C. 
After first round of PCR, reaction mixtures containing mutated 
forward/reserve strands were mixed up and supplemented with additional 0.4 
unit of Phusion enzyme. The same PCR setup was performed but repeated 
with 12 cycles. After that, 1.5 µl of DpnI enzyme was added to 15 µl of PCR 
reaction product and incubated at 37 °C for 2 hrs to clear up the template 
plasmids. 2 µl of digested product was transformed into Omnimax competent 
cells (Invitrogen).   Mutations and all plasmid constructs were confirmed by 
DNA sequencing. 
2.8 Western Blot  
HEK 293 cells were seeded in 6-well plates and transfected with pCDNA6 
plasmids to express wild type and mutated FRs. 3 days after transfection, 
conditioned culture media was collected. Proteins in same amount of media 




were resolved on 4%-15% SDS-PAGE gradient gel (Bio-Rad Laboratories) 
and transferred to PVDF membrane (Thermo Scientific). Blots were probed 
with goat anti-human IgG-HRP (Santa cruz biotechnology).  
2.9 Radioligand binding assay 
The binding affinity of each FRα mutants was determined by saturation radio 
ligand binding assay.  As described in section 2.4.1, FRα mutants were 
prepared by affinity purification. Protein concentration was measured by 
standard Bradford assay. 40 nM of each mutant in 100 μl binding buffer (25 
mM Tris, pH 8.0, 150 mM NaCl and 0.1% triton-X 100) was immobilized in 
the wells of a protein G-coated 96-well plate (Thermo Scientific) for 40 min.  
Endogenous ligand was stripped with 100 μl stripping buffer (25 mM acetate 
acid, pH 3.5, 150 mM NaCl and 0.1% triton X-100) for 1 min as previously 
described [103]. After that, protein was neutralized and washed three times  
with 200 μl binding buffer. Next,  protein was incubated for 40 min with 100 
μl binding buffer supplemented with different concentrations of 3[H]-folic acid 
(0 nM, 0.5 nM, 1 nM, 2 nM, 4 nM, 8 nM, 20 nM, 40 nM, 80 nM, and 100 nM; 
Moravek Biochemicals).  FRα-bound 3[H]-folic acid was determined by 
scintillation counting after removal of unbound ligand by washing three times 
with 100 µl binding buffer.  Dissociation constants were determined by 















3.1 Bacterial expression of FRs 
Bacterial expression system has many advantages over other expression 
systems in terms of handling simplicity, time efficiency, high protein yield, 
and low cost. As a result, bacterial expression is always the primary choice for 
protein expression and purification [142]. 
3.3.1 Screening of bacterial expression tags for FRα  
Protein of interest is routinely fused with various protein tags to improve the 
protein yield, facilitate protein folding and help purification process. The most 
frequently used tags include Glutathione S-transferase (GST) tag, Small 
Ubiquitin-like Modifier (SUMO) tag and Maltose Binding Protein (MBP) tag.  
FRs are firstly translated into pro-proteins in Endoplasmic reticulum, which 
consists of secretion signal peptide in N-terminus and GPI signal peptide in C-
terminus (Fig.6a). Next, these signal peptides are recognized and removed, 
and a GPI linker is added to protein at Ser234. The mature protein is secreted 
and attached to the cell surface through a GPI anchor. Since the bacteria lack 
the recognition and modification machinery for these signal peptides, they are 
excluded in the bacterial expression constructs. 
FRα (23-234) was expressed as H6GST/H6SUMO/H6MBP- fusion proteins in 
a small scale and purified using Ni-NTA agarose beads binding. The purified 
proteins were analysed by SDS-PAGE to determine their final yield. Samples 
were also collected at each step of purification to assess the expression level, 
protein solubility and affinity binding efficiency. As shown in figure 9,  





expressed relatively well, but the recovery rate of this protein was low due to 








Figure 9. Small scale expression of different recombinant FRα proteins. 
FRα was fused with H6GST, H6SUMO, and H6MBP tags. Protein samples 
from total cell lysate (TP), supernatant after centrifugation of TP (SN) and 
elution buffer after purification (EL) were collected and analyzed by SDS-
PAGE. The molecular weight of each recombinant protein is labelled. Purified 
H6GST and H6SUMO-FRα were highlighted by red boxes. 
 
3.1.2 Screening of FRs from different species 
Orthologous FR genes are found in fish, amphibians, birds and mammals, and 
they have relatively high sequence identity between species (Table 3). 
Previous structural studies indicated that even closely homologous proteins 
often have different crystallization properties [143]. So different FR orthologs 
were cloned into H6GST vector and expressed on a small scale to identify 
proteins with a higher expression level. As shown in Figure 10, homo FRα and 




















Figure 10. Small scale expression of H6GST-FRs from different species. 
FRs from human (homo), chicken (gallus), pig (sus), cow (bos), frog (xenopus) 
and salmon (salmo) were cloned into H6GST vector and expressed. Protein 















Homo FR1 77%  72%  68%  71%  64%  55%  61%  
Homo FR2   69%  74%  82%  65%  54%  64%  
Sus FR1    67%  70%  64%  57%  59%  
Sus FR2     81%  61%  55%  58%  
Bos FR      61%  53%  60%  
Gallus FR       64%  68%  





After the screening, the expression of H6GST-homo FRα and gallus FR was 
scaled up to 2 L cultures to further characterize their behaviours.  
Recombinant proteins were first purified by Ni-NTA column, followed by 
separation using size exclusive chromatograph. Two proteins had similar size 
column profile. Majority of the proteins appeared in the fractions 
corresponding to aggregations (F2, 3), indicating they were not correctly 
folded. Besides, degraded proteins (F19, 20, 21) were also observed from the 










Figure 11. 2L expression of  H6GST-homo FRα and gallus FR 
recombinant proteins.  a) size exclusive chromatograph and gel analysis of 
H6GST-homo FR1. b) size exclusive chromatograph and gel analysis of 
H6GST-gallus FR. Recombinant proteins are highlighted in red boxes.  
TP   SN    FT   EL   F2   F3    F19 F20 F21 







3.1.3 Purification and in vitro refolding of MBP-FRα fusion protein 
Initial attempts to express FRs in E.coli failed because the recombinant 
proteins were misfolded and insoluble. After closely examining the protein 
sequence, we found that FRα contains sixteen cysteines which may form eight 
pairs of disulfide bonds in the correctly folded protein. Correct disulfide bond 
formation is always a challenge in bacterial expression system. However, our 
lab has developed a system to overcome the challenges posed by the cysteine-
rich proteins [144]. In this system, E.coli disulfide bond isomerase DsbC is 
firstly co-expressed with the target protein to facilitate correct disulfide bond 
formation. Next, MBP is fused to FR through a non-cleavable short linker 
(NAAAEF) to help the protein to fold. Thirdly, the recombinant protein is 
expressed in Rosseta-gami E.coli strain, which alleviates codon bias and 
enhances disulfide bond formation. Figure 12a clearly shows that the protein 
expression level in Rosseta-gami cells was much higher than in BL21(DE3) 
cells. Following this, large scale expression was performed, however, the 
majority of proteins aggregated (Fig.12b).  
Hence, we then decided to denature the aggregates and refold them in vitro. 
DTT was used to break the misfolded disulfide bonds and urea was used to 
denature the protein. We screened various combinations of different reagents 
concentration, denaturing temperature and time. After denaturization, protein 
was refolded by dialysis against refolding buffer overnight. Native-PAGE gel 
electrophoresis was used to assess the denature-refold efficiency. Figure 12c 






























Figure 12. Purification and in vitro refolding of MBP-FRα fusion protein. 
a) Comparison of MBP-FRα expression in BL21(DE3) and Rosseta-gami cells. 
b) Size exclusive chromatograph and gel analysis of MBP-FRα fusion protein. 
c) Native-PAGE of denatured MBP-FRα using different denaturing conditions.  
Lane 1 2 3 4 5 6 7 
DTT(mM)  0  10  10  10  10  10  10  
Urea(M)  0  2  2  4  4  6  8  
Temp(°C)  0  24  37  24  37  24  24  





3.2  Mammalian expression of FRs 
Given that our findings demonstrated that FRα cannot be properly folded in a 
bacterial system due to the lack of post translational modifications including 
glycosylation and disulfide bond formation, we switched to the mammalian 
expression system. As performed in the bacterial system, the protein of 
interest was firstly fused with different protein tags and screened. Expression 
plasmid was then transfected into HEK 293 cells, and the conditioned cell 
media was collected three days after the transfection. Western blot was then 
performed to determine the expression level of each recombinant protein. 
MBP-FRα-MBP and FRα-Fc recombinant proteins were expressed at 
relatively high levels.  
3.2.1 Transient expression of MBP-FRα-MBP fusion protein 
MBP-FRα-MBP was then cloned in inducible pCZ3 vector and expressed as 
secretion protein. Plasmids were transiently transfected into the FTP7 
suspension cells. After the cell density reached 4×10
6 
cells/ml, protein 
expression was induced by adding 1 µg/ml Dox. Protein was accumulated for 
three days after induction. Folic acid was added into the cell media to promote 
the correct folding of the receptor. Different folic acid concentrations were 
tested and 400 µM folic acid was found to be optimal (Fig.13a). 
500 ml of conditioned cell media was harvested three days after induction and 
concentrated to 100 ml. After dialysis, protein was purified by amylose beads 
binding. The efficiency of each step was closely monitored by dot plot 
(Fig.13b). After that, the proteins were further separated by size exclusive 





















Figure 13. Expression of MBP-FRα-MBP in FTP7 cells. a) optimization of 
induction time and folic acid concentration. b) Dot plot of MBP-FRα-MBP in 
each purification steps. c) Size exclusive chromatograph and gel analysis of 
MBP-FRα-MBP protein. 
 






MBP-FRα-MBP was monomeric according to the size column profile, and the 
purity was over 95% according to SDS-PAGE. Hence, the protein was 
concentrated to 16 mg/ml and crystallization trials were set up, using six 
common screens from  Hampton Research (Crystal Screen, PEG/Ion, SaltRx, 
PEGRx, Index and MembFac screen). Unfortunately, no crystal was observed 
under any of the conditions.        
3.2.2 Stable clone expression of FRα-Fc fusion protein 
We then constructed cell lines stably producing FRα-Fc protein. HEK293 cells 
was transfected with expression plasmid pCDNA6-IgL-FRα-FcH6. Cells were 
diluted until a single colony could be picked up. Each colony was seeded into 
a well in 24-well plate and selected using blasticidin. Cell media from 
surviving clones were tested for the expression of the proteins by biolayer 
interferometry using protein A sensor (Fig.14a). Six stable clones were 
selected and their protein expressions were confirmed by western blot 
(Fig.14b). Similar to MBP-FR-MBP protein expression, the optimal folic acid 
concentration to be supplemented was determined to be 200 µM (Fig.14c). 
Stably transfected cells were maintained in 500 ml media in 1 L roller bottles 
at 37 °C. 2 L conditioned media was collected and concentrated to 400 ml and 
dialyzed before Ni-chelating sepharose column purification. Purified fusion 
protein was digested by thrombin and dialyzed to remove imidazole.  The 
digestion product was purified by Ni-NTA column to remove the FcH6 tag. 
The flow through was collected and finally separated by size exclusive column. 




































Figure 14. Stable clone expression of FRα-Fc fusion protein. a) selection of 
cell colony stably expressing FR-Fc by biolayer interferometry. Clone 4A3 
had an expression level more than 3µg/ml and was selected for large scale 
expression. b)Western blot of established six stable cell lines. c) Different 
concentrations of folic acid were supplemented into culture media and 200µM 
was the optimal concentration. d) Size exclusive chromatograph of FRα 
protein. e) Gel analysis of each purification step. From left to right: elution 
from 1st Ni column, thrombin digestion products, flow through after 2nd Ni 
column, protein from four peak fractions of size column.  
 
3.2.3 Crystallization of wild type FRα protein 
The protein yield from 2 L media was about 1 mg. The purified protein was 
concentrated to 10 mg/ml and initial crystallization screens were set up. 
Needle like crystals were observed in several conditions after screening of six 
Hampton Crystallization Screens (Fig.15a). The crystals were further 
optimized using additive screen, detergent screen (Hampton Research) and 24-
well hanging drop varying concentrations of salts, precipitants and pH. Some 
thicker and bigger needle-like crystals (Fig.15b) were then obtained and sent 
for X-ray diffraction. However, these crystals diffracted poorly with a 




























Figure 15. Crystallization of wild type FRα protein. a) Crystal from initial 
screen. Condition: 0.2M tri-sodium citrate, 20% PEG3350 (index H10). b) 
Crystal from optimization. Condition: 0.2M ammonium sulfate, 0.1M Tris 8.0, 
15% PEG3350, 4% 1,3-propanediol (Index F9+additive screen H3). c) 







3.3 Deglycosylation of FRs 
Homo FRα has three glycosylation sites: N69, N161 and N201. Protein 
purified from the stable clones seemed to be fully glycosylated based on its 
molecular weight (36KD). Unfortunately, glycosylation always poses 
difficulties during crystallization, due to the chemical and conformational 
heterogeneity [132]. There are two strategies which can be employed to 
overcome this glycosylation problem, 1) mutation of glycosylation sites, and 2) 
enzymatic deglycosylation.  
3.3.1 Point mutation of glycosylation sites 
Mutation of glycosylation sites is a straight forward method to completely 
remove all the glycans. There are two types of glycosylation, N-glycosylation 
and O-glycosylation, in which the glycans are attached to Asn residue or 
Ser/Thr residue respectively. Substitution of these residues to Ala will abolish 
the glycosylation process. However, deglycosylation may affect the protein 
expression and normal function. Previous studies showed that single or double 
site-directed mutagenesis didn't decrease the folate binding affinity of FRα 
significantly, whereas  mutation of all three sites eliminated the folate binding 
and the cell surface expression.  In contrast, enzymatic deglycosylation of 
purified FRα had no effect on the folate binding affinity [145].  
Based on these reports, single/double/triple N-glycosylation site mutations 
were constructed and expressed in HEK293 cells. Cell culture media was 
collected and tested by western blot (Fig. 16a). Single point mutations only 
decreased the expression level slightly, whereas double mutations decreased 





completely. Thus the double mutations construct FRα(N69AN201A) was 
selected and stably expressed in large scale (Fig.16b). Size column profile and 
SDS-PAGE showed the protein had a molecular weight of ~28 KD, which was 
corresponded to protein with one site glycosylation (Fig.16c).  
Purified proteins were concentrated to 10 mg/ml and screened using six initial 












Figure 16. Mutational deglycosylation and purification of 
FR(N69AN201A). a) western blot of single/double N-glycosylation site 
mutations. b) Western blot of established FR(N69AN201A)-Fc cell line. c) 
Size exclusive chromatograph and gel analysis of FR(N69AN201A). From left 
to right: FR-Fc from first Ni column purification, thrombin digestion product, 








3.3.2 Endo F3 treatment of FRα 
Enzymatic deglycosylation is widely used in studies to get rid of glycans. 
There is a variety of deglycosylation enzymes with different recognition sites 
and cutting positions [146]. For example, PNGase F cleaves all N-linked non-
fucosylated oligosaccharides, and  deaminates the Asn to Asp at the site of 
deglycosylation. In comparison, Endo H and F series cleave between the two 
N-acetylglucosamine (GlcNAc) residues in the N-linked glycan core, 
generating the protein with one GlcNAc attached to the Asn. This is beneficial 
for the protein because N-linked GlcNAc is shown to be able to shield the 
hydrophobic regions of the protein surface [147]. In contrast, deglycosylated 
proteins generated by PNGase F treatment tend to aggregate [148].  
Thus the WT homo FRα was first treated with Endo F3. Purified FRα was 
digested with Endo F3 at 37 °C for 1 hr with mass ratio 1:25 after pH 
adjustment to 4.6. Digestion products were loaded to size exclusive column 
for further separation (Fig. 17a). Proteins at each steps were sampled and 
analyzed using SDS-PAGE (Fig. 17b). Results suggested that Endo F3 was 
able to cleave FRα, however, multiple products were generated. Size column 
fractions F13 and F14 were concentrated separately to 10 mg/ml and initial 
crystal screens were set up. Some cubical and round shape crystals appeared 
(Fig.17c) but the diffraction was very poor (Fig. 17d). 






























Figure 17. Endo F3 treatment of FRα. a) Size exclusive chromatograph and 
gel analysis of endo F3 treated FR. b) Gel analysis of each steps of purification. 
From left to right: protein marker, FR-Fc after Ni purification, thrombin digest 
product, flow through from 2nd Ni, after endo F3 treatment. c) Crystals of 
endo F3 treated FR. Left: protein from F13, conditions: 0.2M tri-ammonium 
citrate pH7.0, 20% PEG 3350. Right: protein from F14, conditions: 2% 
Tacsimate pH7.0, 0.1M HEPES 7.5, 20% PEG3350. d) Diffraction patterns of 





F11 F12  F13  F14   F15 
3.3.3 Combined treatment of kifunensine and Endo H 
As demonstrated in section 3.3.2, Endo F3 treatment could not completely 
remove all three glycans at once. Thus this treatment generated FRα with one, 
two or three glycans which were still attached. This result was consistent with 
our previous assumption that glycosylation is of a heterogeneous nature. To 
make the glycans more homogenous, we decided to add kifunensine into the 
cell medium. Kifunensine is a potent inhibitor of -mannosidase I, which can 
convert the complex N-glycan to homogenous Man9(GlcNAc)2. In addition, 
this mannose-rich glycan is sensitive to Endo H cleavage, leaving a single 
GlcNAc residue at each glycosylation site [149].   
Following the kifunensine treatment, proteins were purified (Fig. 18a). And 
part of the kifunensine treated proteins were digested using Endo H (Fig.18b). 
Next, they were subject to crystal screen, and both kinds of proteins produced 
crystals in initial screens (Fig.18c, d), which could diffract to about 12 Å 































Figure 18. Combined treatment of kifunensine and Endo H. a) size 
exclusion chromatograph and gel analysis of protein treated with kifunensine 
alone b) size exclusion chromatograph and gel analysis of protein treated 






purification, after thrombin digestion, after endo H digestion, protein from 
peak fractions of size column.  c) crystals obtained from kifunensine treated 
protein. Condition: 0.1M BIS-TRIS 6.5, 20% PEG1500, 6.5mM n-Nonyl-β-D-
glucoside). d) crystals from endoH digested protein. Condition: 12% PEG20K, 
0.1M MES 6.0. e) and f): diffraction patterns of c and d.  
 
However, the crystals of kifunensine treated proteins could not be optimized 
further to a higher resolution. In contrast, after several rounds of optimization, 
proteins which have been treated with Endo H and kifunensine gave rise to a 
plate shaped crystal in a sitting drop containing a reservoir solution of 12% 
PEG20, 000, 0.1 M MES pH 6.5, and 0.1 M sodium potassium tartrate. The 
crystal diffracted to 2.8 Å (Fig. 19). 







Figure 19.  Optimized Crystal of Endo H treated FRα protein. a) Crystal. 







3.4 Structure determination 
3.4.1 Molecular replacement 
A full dataset of deglycosylated FRα crystal described in last section was 
collected at 21-ID-G (LS-CAT) of advanced photon source at Argonne 
National Laboratory (IL, US). Data was processed by HKL2000 and the 
statistics of data collection is summarized in table 4.  
Table 4. Statistics of data collection for deglycosylated FRα. 
*Values in parentheses are for highest-resolution shell. 
First of all, we tried to use molecular replacement (MR) method to solve the 
structure. MR is a easy way of solving phase problem in X-ray crystallography. 
The structure of a homologous protein serves as a very first model that can 
subsequently be refined. After searching the protein databank, chicken 
riboflavin binding protein (RfBP) gave the highest score for similarity. 
However,  RfBP and FRα only share 22% sequence identity, which suggests 
their structures may differ a lot from each other. Besides, the cell unit 
dimension of the crystal was quite large and the Matthews coefficient 
predicted that there are eight to twelve molecules in one asymmetric unit. All 
of these factors made the searching and refinement using MR very 










Cell parameter 90.883, 143.859, 216.260,90,90,90 
Total reflection/unique reflection 781821/64025 
completeness 100%(100%)* 
I/σ 56.9/2.9 (6.0/2.4)* 





3.4.2 Isomorphous replacement 
Isomorphous replacement is another method to solve phasing problem in X-
ray crystallography. In this method, the X-ray diffraction pattern of a native 
protein crystal is compared with that of a crystal of the same type but 
containing at least one heavy atom. The derivative crystal should be identical 
to the native one except for the attached heavy atoms. Coordinates of these 
heavy atoms in the unit cell are determined first and the protein phase angles 
are calculated.  
The initial step in isomorphous replacement requires the attachment of the 
heavy atom. In order to identify the heavy atoms, which are able to bind to the 
protein, different heavy atom salts were screened by incubating them with 
protein in solution and analysing them in native gel. A band-shift from native 
protein indicated that the protein was bound with the heavy atom. Figure 20 
suggested that KAuCl4 and AgNO3 denatured the protein, whereas platinum 
(Pt) salt can be used to soak the protein crystal.  
Dozens of deglycosylated FRα crystals were produced as described in section 
3.3.3. Different Pt salts including KPt(CNS)6, K2PtBr6 and (NH4)2PtCl4 were 
added to the droplet containing the crystal. The final concentration of Pt salts 
in each droplet was 5 mM. Protein crystals were soaked for 20-24 hrs and no 
obvious damage in crystal was observed. The soaked crystals were mounted 
and several diffraction datasets were collected. One of the dataset was used to 
















Figure 20. Native gel analysis of interaction of protein with heavy atom 
salts.  
 
3.4.3 Single anomalous diffraction  
Single anomalous diffraction (SAD) is another method to determine the 
diffraction phases. A lower energy incident X-ray can be absorbed to bring 
about the transition, which reduces the coherent scattering. This anomalous 
scattering can be detected and used for phase determination. And this effect is 
general stronger for heavier atoms. Most commonly SAD experiments exploits 
selenomethionyl proteins, which is difficult and costly to produce for protein 
expressed in mammalian system. Recently, Qun Liu, et al. published a paper 
in demonstrating the practice of SAD using intrinsic anomalous scattering 
from native sulfur to solve a protein structure [136]. Anomalous signals for 
light elements increase as energy decreases, and according to the paper, the 
optimal X-ray energy for samples of sizes around 200µm is 7 KeV.  However, 
Lanes Heavy atom salts 
1 Gold potassium cyanide  KAu(CN)2 
2 Potassium tetrachloroaurate KAuCl4 
3 Mercury chloride HgCl2 
4 Ethylmercury chloride C2H5HgCl 
5 Mercury iodide HgI2 
6 Ammonium tetrachloroplatinate (NH4)2PtCl4 
7 Potassium tetracyanoplatinate K2Pt(CN)4  
8 Lead acetate Pb(CH3COO)2 
9 Silver nitrate AgNO3 
10 WT protein 





low energy will also cause radiation damage due to increased X-ray absorption, 
which will reduce the signal-to-noise ratio. To enhance the signal to noise 
ratio, several datasets were collected and merged together to increase the data 
multiplicity.  
By combining the phase information from Pt-derived crystal and sulfur 
anomalous data, the structure of FRα was successfully solved. The statistics of 
structure refinement is shown in table 5. PDB code is 4LRH. 
Table 5. X-ray diffraction data and refinement statistics. 




Data collection    
Space group P212121 P212121 P212121 
    






α,  β, γ ()  90, 90, 90 90, 90, 90 90, 90, 90 
Wavelength (Å) 0.9787 1.77 1.008 
Resolution (Å) 50-2.8 50-3.0  50-3.55 
Rsym or Rmerge 0.150(1.23) * 0.311(2.77) *
#
  0.126(0.939) * 
I / σI 15.2(1.8) * 24.5(1.9) * 22.0(2.7) * 
Completeness (%) 99.9(99.8) * 100.0(100.0) * 100.0(100.0) * 
Redundancy 14.1(11.9) * 75.5(54.2) * 14.6(14.1) * 
FR per asymmetric unit 8 8 8 
    
Refinement    
Resolution (Å) 50-2.80   
No. reflections 70805   
Rwork / Rfree 20.6%/25.6%   
No. atoms    
    Protein 13568   
    Ligand/ion 256   
   Water 208   
B-factors    
    Protein 68.5   
    Ligand/ion 62.0   
    Water 54.2   
R.m.s deviations    
    Bond lengths (Å) 0.0114   
    Bond angles () 1.60   
*Values in parentheses are for highest-resolution shell. # Note that the sulfur 






3.5 Overall structure of FRα and ligand binding pocket 
Folate receptor is a globular protein consisting of six helices, two pairs of β-
sheets and many loop regions. The overall structure is stabilized by eight 
disulfide bonds (C15-C43, C35-C83, C44-C87, C67-C153, C74-C124, C113-
C187, C117-C167 and C130-C147). As expected, GlcNAc is observed in each 
predicted N-glycosylation site (N69, N161 and N201). (Fig. 21a) 
FRα has a deep binding pocket with one end open, which accommodates folic 
acid with its pteroate moiety buried inside and glutamate group sticking 
outside. The binding pocket is formed by α1/α2/α3 in the back, the N-terminal 
loop/β1/β2 in the bottom, the α1-α2 and α3-α4 loops in the left and top, and 
α4/α5/β4/β3 in the right (Fig. 21a).  The overall structure looks like folic acid 
is gripped by a hand. Fig 21b shows the structure from another angle of view.  
Folic acid is almost perpendicular to the plane formed by helix α1, α2 and α3, 
which is the palm of the hand. Whereas the N-terminal loop,  loops between 
α1-α2, β1-β2 and α3-α4 are the fingers which grip the folic acid in middle. 












Figure 21. Overall structure of FRα-folic acid complex. a) Structure of FRα 
bound to folic acid. Folic acid is shown in grey, N-acetyl glucosamine in 
orange, and the disulfide bonds are depicted as yellow sticks. The N-and C-
terminus are labelled as N and C. b) Another view of complex structure. Folic 
acid is held by the hand formed by FRα. Loop fingers are labelled.  
 
Clear electron density was observed for folic acid and the surrounding amino 
acid residues, which allowed accurate modeling of the ligand and its 
interacting residues lining the binding pocket (Fig. 22a).Surface charge 
distribution was calculated and presented in Fig. 22b. The α1-α2, β1-β2, and 
α3-α4 loops form the entrance of the binding pocket, which is positively 
charged and interacts with the negatively charged carboxyl groups of folic 
acid. The internal charge distribution surface was shown in Fig.22c. The cross 
section of the binding pocket reveals the complementary shape and charge 
between the bound ligand and the receptor. The basic pteroate head of folic  
acid is buried within the negatively charged inside part of the pocket, whereas 
the acidic tail of the ligand interacts with the positively charged outside part of 






















Figure 22. Surface charge distribution of FRα. a) The σA-weighted 2Fo-Fc 
electron density map for folic acid shown as a grey mesh. b) surface of FRα 
with a close-up view of the ligand-binding pocket entrance.  Folic acid carbon 
atoms are colored grey, nitrogen atoms blue, and oxygen atoms red. c)The 
internal charge distribution surface of the binding pocket with folic acid 
shown in stick presentation. A color code bar (bottom) shows an electrostatic 
scale from -3 to +3 eV. 
 
 
The crystal structure also revealed the detailed folic acid binding mechanism 
of FRα. Extensive interactions were observed between the receptor and the 
pteroate head of the folic acid. Firstly, the pterin ring is stacked between the 
parallel side chains of Y85 and W171, and capped by Y175. Secondly, a series 
of hydrogen bonds were found to stabilize the hydrophilic pterin ring. 
Specifically, the pterin N1 and N2 atoms form strong H-bonds with the side 
chain carboxyl group of D81, the N3 and O4 atoms with the S174 hydroxyl 
group, the O4 atom with guanidium groups of R103 and R106, and the N5 
atom with the H135 side chain (Fig. 23a,b). In addition, the aminobenzoate 
moiety of folic acid is stabilized by hydrophobic interactions with Y60, W102, 
and W134, which line the middle of the long ligand-binding pocket (Fig. 23b). 
Finally, a number of interactions are also observed for the glutamate group, 
which engages six H-bonds, contributed by the side chains of W102, K136, 
and W140, as well as by backbone interactions of H135, G137, and W138 (Fig. 





Remarkably, all residues involved in ligand-binding are conserved among 
different subtypes of FR regardless of their species origin, which suggests the 
ligand binding mechanism is highly conserved during the evolution (Fig. 24). 
























Figure 23. FRα-folic acid interactions. a) Folic acid-binding network with 
close-ups of the folic acid head and tail groups.  Residues that line the binding 
pocket are shown in green and folic acid in grey.  Hydrogen bonds are 
indicated by dashed lines. b) Interaction map of folic acid with ligand-binding 
pocket residues. The folic acid chemical structure is shown in magenta, pocket 
residues in black, and hydrogen bonds as green dashed lines with bond 
distances (Å) indicated.  Hydrophobic interactions are presented as curved red 
lines.  The pteroate and glutamate moieties of folic acid are indicated above 
the map. 
 
Figure 24. Sequence alignment of FRs from different species. The 
alignment includes subtypes from five different species: human (homo), pig 
(sus), cow (bos), Xenopus (xen) and salmon (salmo). Numbers (1-3) denote 
FR α, β, γ subtypes. Secondary structure elements of human FRα are indicated 
above the sequences (cylinders: α-helices, arrows: β-strands). Stars below the 
sequences denote cysteine residues, circles denote N-glycosylation sites, and 






3.6 Mutagenesis and ligand binding assay 
To validate the structural observations, each of the residues interacting with 
folic acid was mutated to Alanine and their effects on ligand binding were 
studied. The site-directed mutagenesis was carried out using the QuickChange 
method. Mutant proteins were expressed in HEK293 cells after transient 
transfection. Western blot was performed to assess the expression of each 
mutant. W171A abolished the protein expression, suggesting it is essential for 
protein stability. All the other mutants could be expressed and purified on a 
small scale (Fig. 25). 
 
Figure 25. Expression of FRα mutants. Each lane contains equal amounts of 
culture medium from HEK293 cells transiently transfected with the indicated 
wild type or mutant FRα expression construct. 
 
Before testing the ligand binding ability of FRα mutants, the binding affinity 
of wild type protein was determined first. Purified protein was immobilized in 
Protein A agarose beads, and the endogenous ligand was stripped away by 
washing with acetate buffer (pH 3.5). Protein was neutralised and incubated 
with different concentration of 
3
[H] folic acid. The bound ligand was 
quantified by scintillation counter. Binding curve was plotted and Kd was 
calculated by nonlinear regression. In addition, although receptor's ligand 
binding affinity was reported to remain unchanged after enzymatic 





treatment of kifunensine and Endo H was determined (Fig. 26). Both wild type 






Figure 26. Binding curves of  wild type and deglycosylated FRα. 3[H] folic 
acid binding assay for Kd determination of purified protein before and after 
deglycosylation. Error bars indicate SD (n=2). Proteins were analysed by 
SDS-PAGE gel.    
Subsequently, the binding curves of all the mutants were measured (Fig. 27a), 

















Figure 27. FRα mutant ligand binding assays. a) 3[H]-folic acid binding 
curves for WT and FRα mutants. b) histogram of Kd values determined from 
binding curves. Fold increases from WT were indicated on top of each bar. 
Error bars indicate SD (n=2).  
 
The most dramatic change was observed following the replacement of D81, 
which decreased the affinity by more than one order of magnitude. This is 
consistent with our observation that D81 forms a pair of strong H-bonds with 
pterin N1 and N2 (bond lengths are 2.9Å and 3.0Å respectively), suggesting 
that this interaction is a key contributor to high affinity ligand-binding. In 
contrast, mutations of Y175, K136, and R106 have little effects on ligand 
binding, and mutations of all other ligand-binding residues only weaken the 
folic acid binding moderately (affinity deceases of ≤ 3.6-fold). This led us to 
conclude that the extensive interaction network makes FRα-folic acid binding 
remarkably resistant to single point mutations. And the high affinity ligand-
binding may result from the collaborated contributions from all residues 
interacting with the ligand. To test this hypothesis, FRα proteins with double 
mutations were expressed and purified, and their binding affinities were 





combination with D81A led to a complete loss of binding, which provided 
additional evidence for that D81 was essential for ligand binding. Moreover, 
combination of R103A/S174A and W102A/R103A resulted in a further 
decrease in binding affinity compared to that caused by any mutation alone 
(Fig.28b and Fig. 27b). These results support our hypothesis that the strong 
ligand-receptor binding comes from the additive contributions from each 









Figure 28. Expression and binding curves of FRα double mutants. a) 
Western blot of FRα with two of folic acid-contacting residues mutated. b) 
3
[H]-folic acid binding curves for R103A/S174A and W102A/R103A. The Kd 
values were presented in Fig. 27b. Binding signals were undetectable for 















4.1 Structure comparison between FRα and chicken RfBP 
Hugo L. Monaco solved the crystal structure of chicken RfBP in 1997 and has 
proposed the structural homology between RfBP and FRs based on the 
sequence alignment [130]. Indeed, the determined FR structure has a notebly 
similar fold as the structure of RfBP. Superposition of two structures yields a 
root mean square deviation (rmsd) values of 1.5 Å for their Cα atom positions 
(Fig. 29a). Their helical structures are mostly conserved. Moreover, the 
arrangement of eight out of nine disulfide bonds in RfBP structure is identical 
to the FRα structure (Fig. 29b). The major difference resides in the C-terminal 
portion. The last two α helices of RfBP and the disulfide bond connecting 
them are absent in FRα. In addition, the antiparallel β strands of RfBP are 
located at top of the binding pocket, whereas those of FRα are located at the 
bottom.  
Despite the similarity in overall structure, careful comparison of ligand 
binding pockets reveals different binding mechanisms employed by the two 
receptors for their respective ligands. The flat riboflavin is accommodated in a 
binding pocket that is wide and shallow. In contrast, the relatively linear folic 
acid molecule fits well in the FRα binding channel, which is long and deep. 
Loops that line up the pocket entry of RfBP are all shifted outward compared 
with that of FRα. Furthermore, riboflavin has an amphipathic isoalloxazine 
ring with its hydrophobic part buried inside a highly hydrophobic groove of 
the binding cavity. On the contrary, the hydrophilic pterin ring of folic acid is 
facing inside and forms a series of hydrogen bonds with FRα residues. 
Remarkably, despite the differences, two hydrophobic residues packed in 





structures, i.e. Tyr75 and Trp156 residues of RfBP and the corresponding 
Tyr85 and Trp171 residues of FRα, which stack the isoalloxazine/pterin ring 
in between for both receptors. Finally, although the pterin head of folic acid is 
positioned near the isoalloxazine ring of RfBP, a kink in C9 of folic acid 
bends the molecule and makes the rest of two ligands point in different 
directions. Thus, the glutamate moiety of folic acid is stabilized by the α3-α4 
loop, while the tail of riboflavin forms several H-bonds with α2 and the α1-α2 
loop.  
As mentioned in section 3.4.1, human FRα and chicken RfBP only share 22% 
sequence identity. Our study demonstrates that these two dissimilar sequences 
appear to be structural homologues. Structural resemblance of proteins implies 
their functional similarity. Indeed, FRα and RfBP bind to folate and riboflavin, 
two members of vitamin B family, and mediate their uptake by endocytosis. 
Remarkably, FRα and RfBP utilize customerized binding pockets to bind to 

























Figure 29. Comparison of FRα and chicken riboflavin binding protein. a) 
Two views of the structural alignment between the FRα–folic acid complex 
and chicken RfBP–riboflavin complex. FRα is colored in magenta, folic acid 
in grey, RfBP in green, and riboflavin in yellow. b) Sequence alignment of 






4.2 Structure of FRβ and pH-dependent ligand release mechanism  
Based on the observation that all the residues involved in ligand binding in 
FRα are conserved in FRβ and γ, we proposed that they share the same ligand 
binding mechanism. One month after the publication of human FRα structure 
by our group, Dr. Dann's group from Indiana university published the human 
FRβ structure in complex with folic acid and antifolates [150]. Their findings 
strongly support our hypothesis. In addition, they solved apo-FRα structure in 
acidic condition, which revealed the pH-dependent release mechanism of folic 
acid from FRs. In the following section, FRα/β structures will be compared 
and the ligand release mechanism of FRs will be discussed. 
FRα/β comparison 
FRα and β shares a sequence identity of 82%, and as expected, the overall 
structure of FRα and FRβ are very similar. Figure 30a presents superimposed 
FRα/β structures, which illustrates conserved secondary elements and tertiary 
structure in FRα and FRβ. In addition, FRα/β also have very similar ligand 
binding pockets (Fig. 30b). Only two residues involed in ligand binding are 
different in FRα/β structure. V107 and K136 in FRα are substituted by 
residues with similar propertities, F123 and R152 in FRβ. The respective 
hydrophobic interation and hydrogen bond contributed by these two residues 
are conserved in FRβ. All the other residues in contact with folic acid assume 
the same conformations and positions in both strucutures. As a result, the 
ligand binding mechanisms are identical for the two receptors. Notebly, the 
pterin ring is stacked between Y85/Y101 and W171/W187 (residues from 





group interacts with receptor through hydrophobic packing. And finally, the 
















Figure 30. Structure alignment of human FRα and FRβ. a) Two views of 
superimposed structures of FRα and FRβ. FRα is colored in green and FRβ is 
colored in magenta. b) Alignment of  ligand binding pocket. All residues 






pH-dependent release mechanism  
Through the structures of FRs-folic acid complexes disclose the binding 
mechanism of receptor in detail, the release mechanism has remained elusive. 
FRs mediate folate uptake through endocytosis. Folate release is proposed to 
be induced by endosome acidification. Remarkably, Dr. Dann's group solved 
the crystal structure of  apo-FRα at pH 5.5, which provided critical insight on 
the pH-dependent folate release mechanism.   
Figure 31a presents pH-induced structural changes of FRα. Significant 
changes were observed at N terminus. Loop region C15-K24 containing a 
conserved KHHK basic motif is denoted as a basic loop, which moves away 
from helix α2. The loop after the basic loop (G26-C35) is named as anchor 
loop, which shifts towards the binding pocket. Helix α1 is also labelled as a 
switch helix because it switches to a loop conformation in acidic state and 
gives way to the anchor loop. Finally, a loop region (P93-L108) adjacent to 
binding pocket moves inward and sits in the binding pocket, which is denoted 
as the inhibitory loop in the figure. The acidic conformation is stablized by a 
series of ionic interactions: D29-H32-E86-R103 (Fig.31b). In the complex 
structure, R103 lines up the binding pocket and interacts with O4 of pterin ring. 
In contast, in acidic conformation, the side chain of R103 is positioned inside 
























Figure 31. Structure of FRα in acidic state. a)  Two views of superimposed 
structures of FRα in neutral and acidic states. FRα in neutral state is colored in 
green and FRα in acidic state is colored in magenta. Folic acid is colored in 
grey. b) Ionic interations stabilize acidic state of structure. PDB code: FRβ in 






Histidine was thought to be important for the pH-induced global structural 
changes, because it is most likely to be ionized at pH range of 5~7. To confirm 
this hypotheses, Dr. Dann's group compared the positions of histidines in 
neutral and acidic states. Interestingly, H135, which is involved in ligand 
binding directly, showed no positional change in the two states. This suggests 
that H135 may play no role in pH-induced conformational change. In contrast, 
H20, H21 in basic loop, H32 in anchor loop and H53 in switch helix change 
their positions dramatically at different PH. In acidic pH, H20 and H21 get 
ionized and exposed into protein surface. The movements of the basic loop 
and switch helix displace the anchor loop, which allows H32 to form the 
critical ionic bridge with R103. Based on these observations, the authors 
concluded that H20, H21 and H32 mediate the structural rearrangement of FRs 
due to ionization in acidic pH.  
Next, Dr. Dann's group determined the dissociation constant of FRα in 
different pH using isothermal titration calorimetry (ITC). ITC seems to be a 
more sensitive method than radioligand binding assay. The receptor's affinity 
determined at neutral pH by ITC was 20-fold higher than that determined by 
our group using the radioligand binding assay. In addition, Dr.Dann's group 
reported a more than 2000-fold decrease in affinity at pH6.5, which was not 
observed in our study. Indeed, in radioligand binding experiment, a dramatic 
decrease in affinity was observed around pH4.  
The physiological pH for FR-containing endosome was reported to be mildly 
acidic (pH6.5) [151]. At this pH, the affinity of the receptor is in the 
nanomolar range despite the method used to determine it. It remains to be 





the folate. Additional intrinsic and extrinsic factors may also play a role in the 
release of folate.  
Some clues come from a previous study of the membrane-bound Niemann-
Pick C1 (NPC1) extracellular domain, which shares some structural similarity 
with FRα [152]. Membrane bound NPC1 and soluble NPC2 mediate the exit 
of the endocytosed cholesterol from the lysosome. Kwon, et al proposed that a 
pocket to pocket interaction between NPC2 and NPC1 may feed the 
cholesterol from NPC2 to N-terminal domain of NPC1. Cholesterol, in turn,  
will be passed to transmembrane domain of NPC1 before egressing the 
lysosome [152]. Since PCFT has been shown to co-localize with FRα in the 
endosome and accelerate the export of endocytosed folic acid, we 
hypothesized that PCFT may interact with FRα so that the release of folate 
from FRα is directly coupled to its transport by PCFT. More biochemical and 
structural studies are needed to establish their interactions and provide further 






4.3 Structure-based rational drug design 
Traditional methods of drug discovery relies on trial-and-error testing of 
compounds on cultured cells and animal models. The recent explosion of 
genomic, proteomic and structural information fuels the development of 
structure-based rational drug design. The rational drug design is a process of 
finding new drugs based on the knowledge of a biological target, modulation 
of which, will result in a therapeutic benefit to the patient. The development of 
bioinformatics accelerates the identification of excellent drug targets. The 
three dimensional structure information generated from X-ray crystallography 
and NMR spectroscopy aids in the design of candidate drugs with high affinity 
and selectivity. In principle, the process of rational drug design includes 
identification of drug targets, structural study of the targets, finding lead 
compounds by screening the existing compound library or de novo building of 
the ligand, followed by evaluation of drug leads (Fig. 32). This process has 
become an integrated part of drug discovery in pharmaceutical industry today 
[153].  
As discussed in Chapter 1, folate metabolism is critical for cancer 
development. Since the discovery of first antifolate in 1950s, the burgeoning 
knowledge of folate-dependent pathway provides more drug targets to attack, 
such as GRAFT, AICARFT and TS. New antifolates have been invented using 
structure-based drug design after structures of these folate metabolism 
enzymes were solved. Structural studies leading to the discovery of antifolates 























4.3.1 DHFR structure and drug discovery 
Crystal structure of E.coli DHFR which was determined in 1977, was the first 
structure of folate-dependent enzymes [154]. DHFR catalyzes the reduction of 
DHF to THF, using NADPH as electron donor. THF is essential for purine and 
thymidylate synthesis, thus inhibition of DHFR can limit the cell growth and 
proliferation. Indeed, the first antitumor antifoalte MTX is a competitive 
inhibitor of DHFR.  
DHFR family is conserved across the species ranging from bacteria to 
vertebrates. DHFR inhibitors, such as trimethoprim and sulfamethoxazole, 
have been used as antibacterial agents for decades [155]. Structures of DHFR 
from different species have been solved in complex with a variety of ligands 
and inhibitors. They share similar tertiary structures despite divergent primary 
sequences (~30% homology). However, kinetics and rate-limiting steps differ 
between pathogenic and human DHFRs, a key observation which has been  
exploited in the pursuit of developing selective antimicrobial drugs [156]. 
Figure 33 showed the crystal structure of human DHFR/NADP+/folate 
complex [157]. The overall structure of DHFR consists of an eight-stranded β 
sheet with four α helix connecting β1-β2, β2-β3, β4-β5 and β5-β6 respectively. 
All the β strands are parallel to each other except for the C-terminal β8 [158]. 
Folate is held in a conformation with its pterin ring perpendicular to its 
benzoyl glutamate tail. The pterin head is inserted between β1β6 and α1, 
whereas its benzoyl glutamate tail is stablized by α1 and α2 (Fig.33b). One 
face of pteridine ring is in close vicinity of NADPH, which allows the transfer 





involved in folate binding. Specifically,  I7, A9 and V115 interact with the 
pterin head, whereas F31, F34, I60 and L67 are lined up around benzoyl 
glutamate moiety. In addition, folate is directly bound with four hydrophilic 
residues. Firstly, side chain of T136 forms one hydrogen bond with 2-amino 
group of petrin head. Secondly, E30 forms a pair of hydrogen bonds with 2-
amino group and N3 simultaneously. E30 also binds to O4 of folate via an 
intervening water molecule. Thirdly, guanidium group of R70 is hydrogen 
bonded to two oxygen atoms of α-carboxylate of glutamate. Finally, N64 
forms a hydrogen bond with carboxyl oxygen of benzoyl group directly, and 
with δ-carboxyl oxygen of glutamate group via an intervening water molecule 
(Fig. 33b). 
The crystal structure of DHFR in complex with MTX has been solved as well. 
Surprisingly, MTX is accomodated in the same binding pocket as folate with 
its pteridine ring in the inverse orientation compared to folate. Figure 33c 
illustrates the overlapping DHRF structures in complex with folate and MTX 
respectively. DHFRs in the two complex structures superimposed well with 


























Figure 33. X-ray crystal structure of human DHFR in complex with 
NADP+ and folate/MTX. a) Overall structure of DHFR/NADP+/folate 
complex in two views. NADP+ is labelled as cyan stick and folate as gray 
stick. PDB code: 4M6K. b) Folate binding pocket. Folate is colored gray and 
residues interacting with folate are labelled as green lines. Hydrogen bonds are 
indicated as yellow dashes with distance indicated. c) Superimposed DHFR 
structures in complex with folate (green) or MTX (magenta). Folate is lablled 
in gray stick, MTX in pink. Residues forming H-bond with MTX pterin head 





residues in two complex structures. In contrast, the flip-over of pteridine ring 
in MTX introduces two more H-bonds with the protein. 4-amino group of 
MTX forms a pair of H-bonds with the main chain carbonyl groups of I7 and 
V115. Meanwhile, the H-bonds formed by E30 and T136 are intact in the 
MTX complex structure. These hydrogen bonds explain the 1000 times 
stronger binding of MTX to DHFR than folate. 
Immediately after the discovery of DHFR structure, scientists started to design 
new DHFR inhibitors based on its X-ray crystal structures. The major 
development comes from the anti-bacterial drug  design for infectious diseases. 
Several lines of species-specific DHFR inhibitors were reported to treat a 
range of diseases, such as tuberculosis [159], opportunistic infections in AIDS 
[160],  and malaria [161]. However, the attempt to design a new generation of 
DHFR inhibitor for antitumor treatment has been unsuccessful. MTX remains 






4.3.2 GARFT structure and AG2034 discovery 
The success of MTX illustrates the usefulness of targeting folate-dependent 
enzymes in antitumor treatment. Consequently, scientists channeled their 
efforts into studying the chemical roles of folate enzymes other than DHFR 
and exploring their potential as an anticancer drug target.  
GARFT catalyzes the transfer of a formyl group from 10-formylTHF to 
glycinamide ribonucleotide (GAR), which is an important step in purine 
biosynthesis. The advantage of selectively targeting de novo purine production 
is based on the assumption that depletion of purine can limit DNA synthesis 
and repair and affect cellular energetics by exhaustion of ATP and GTP stores 
[162]. In addition, cancer cells could be more vulnerable to purine deficiency 
due to the lack of enzymes involved in purine salvage. In 1980s, Grindey and 
his colleagues identified a novel antifolate targeting GARFT - lometrexol 
(Fig.34), and demonstrated its antitumor activity [65, 163].  Lometrexol 
showed activity against a number of tumor lines which were unresponsive to 
MTX, thus expanded antifolate family[164].  
However, severe side effects were observed in the phase I clinical trial of 
lometrexol [68]. Although folic acid supplementation was suggested to 
prevent toxicity, the clinical trials studying the combination administration of 
lometrexol and folic acid yielded discouraging results [165]. Despite its 
serious toxicity, lometrexol represents a very interesting calss of antitumor 
drug because it is the first selective inhibitor for de nove purine synthesis 
pathway and it can induce positive clinical responses in several hard to treat 







Figure 34. Chemical structures of GARFT inhibitors: lometrexol and 
AG2034.  
Structure of E. coli GARFT in complex with its substrate GAR and inhibitor 
lometrexol was determined in 1992, which paved the way for the design of 
new GARFT inhibitors [166]. GARFT consists of seven β strands and six α 
helix in the order of β1-α1-β2-α2-β3-α3-β4-α4-β5-α5-β6-β7-α6, followed by 
an extended C terminal loop. The overall structure contains a central core of 
twisting seven-stranded β sheet surrounded by six α helix on both sides. All β 
strands in this sheet are parallel to each other and have the same polarity 
except for β6 (Fig. 35a).  
The active site is located at the cleft between β4 and β5. The ligands interact 
with the C-terminal part of β4 and β5, as well as the residues from α1 and α6, 
and the loops connecting them. GAR-binding site is quite conserved in a 
variety of nucleotide-binding proteins. The main-chain NH groups of G11, 
S12 and N13 from helix α1 interact with the terminal three oxygen atoms of 
phosphate group of GAR. In addition, the side chains of Q170, D173 from 
helix α6 form H-bonds with the fourth oxygen of phosphate group and the 







The inhibitor binding site is demonstrated in Figure 34c. The bicyclic domain 
of lometrexol is buried inside and the glutamate group is at enzyme surface. 
The bicyclic domain is surrounded by tightly packed hydrophobic residues 
including L85, F88, L92, P96, V97, L104 and V139. The benzoyl ring is also 
stablized by several hydrophobic residues including M89, I91, L118 and L143. 
In addition, main-chain groups of R90, L92, D141 and D144 form several H-
bonds with the bicyclic ring to facilitate binding. 
Based on the X-ray crystal structure of GARFT/GAR/lometrexol complex, a 
research group from Agouron Pharmaceuticals Inc. computationally analyzed 
the GARFT active site and proposed that two sulfur subsititutions should grant 
the compound higher affinity to the binding site. As a result, AG2034 was 
synthesized as a second generation of GARFT inhibitor (Fig. 34). AG2034 is 
more potent than lemotrexol and displays broad spectrum antitumor activity in 
vitro and in vivo [69]. Unfortunately, dose-limiting toxicities prevailed in 
phase I clinical trials and no objective antitumor responses were observed in 




























Figure 35. X-ray crystal structure of E.coli GARFT in complex with GAR 
and lometrexol. a) Overall structure of GARFT/GAR/lometrexol complex in 
two views. GAR is labelled as cyan stick and lometrexol as gray stick. b) 
GAR binding pocket. GAR is colored cyan and residues interacting with GAR 
are labelled as green sticks. Hydrogen bonds are indicated as gray dashes. c) 
Lometrexol binding pocket. Lometrexol is lablled in gray, hydrophobic 
residues around bicyclic domian in pink, residues stabilizing benzoyl ring in 





4.3.3 TS structure and Nolatrexed discovery 
TS catalyzes the methylation of dUMP to dTMP using 5,10-methyleneTHF as 
one-carbon donor. This is a critical step in de novo thymidylate synthesis and 
the therapeutic value of TS has been demonstrated by the clinical activity of 
its inhibitor-raltitrexed. Raltitrexed is a classical antifolate, which contains a 
glutamate moiety and is water-soluble (Fig. 36). Raltitrexed is transported into 
the cells by RFC and FRα. After entering the cell, it is rapidly 
polyglutamylated by FPGS, which enhances its inhibitory potency. Hence, 
drug resistance can be acquired by mutations in genes encoding transporters, 
FPGS or polyglutamates hydrolyase. To overcome resistance, researchers 
designed a new class of lipophilic antifolate, which can exert its cytotoxic 
activity independent of active transportation and  polyglutamylation. This 
strategy was successfully exploited by Agouron Pharmaceuticals in the design 
of nolatrexed (Fig. 36) using structure-based drug design [168].  
 
 









Crystal stucture of Lactobacillus casei TS was first solved in 1987 [169], 
followed by the determination of its ortholog structures from E.coli, rat and 
human [170-172]. As expected from the highly conserved primary sequences, 
the structures of TS from different species are very similar. Human TS was 
crystallized in complex with dUMP and raltitrexed, which revealed its 
structure-activity relationship. As presented in Fig. 37a, TS is a dimer of two 
identical subunits stacked onto each other through a five-stranded β sheets 
(β2-6). The tertiary fold of TS monomer is arranged in three layers. The 
central layer is composed of helice α8 in the middle flanked by α5, α6, α7 and 
α1β1 on each edge of the middle layer. One side of the central layer is the 
five-stranded β sheet. The other side of the central layer consists of α2, α3, α4 
at the bottom and α10 with antiparallel β7, β8 at the top (Fig. 37b).  
The binding pocket is formed by the turning part of the five-stranded β sheet, 
N -ternimal regions of α2 and α8, the loop regions connecting them and a 
small loop region between β3 and α6 of the other mononer. 
As shown in Figure 37c, dUMP is covalently linked to TS through C195. In 
addition, a series of H-bonds tightly anchored dUMP into the binding pocket. 
The uracil base group forms H-bonds with H196, Q214 and N226 respectively. 
Moreover, the 3' hydroxyl group of deoxyribose forms a pair of H-bonds with 
side chains of Y258 and H256. Finally, the phosphate group is stabilized by 
five residues, among which, R50, S216 and R215 come from the same 
monomer, whereas, R175 and R176 come from the other TS monomer.  
Unlike dUMP, raltitrexed is mainly stabilized by hydrophobic interaction. The 





rings of dUMP. Residues M311, W109, I108, F225, F80 and L221 line up the 
hydrophobic channel. Besides, two H-bonds are formed between the bicyclic 
ring of raltitrexed and the main chain of G222 and the side chain of D218 
respectively, which further stabilize the binding (Fig. 37d).  

































Figure 37. X-ray crystal structure of human TS in complex with dUMP 
and raltitrexed. a) Human TS is in homodimer structure. b) Overall structure 
of TS/dUMP/raltitrexed complex monomer in two views. dUMP is labelled as 
cyan stick and raltitrexed as gray stick. c) dUMP binding pocket. dUMP is 
colored cyan and residues from same subunit interacting with dUMP are 
labelled as green sticks. Residues from the other TS monomer are labelled 
magenta. Hydrogen bonds are indicated as gray dashes. d) Raltitrexed binding 
pocket. Raltitrexed is lablled in gray, hydrophobic residues around ligand in 






Nolatrexed was designed by an iterative process founded on the knowledge of 
three-dimensional structure of E. coli TS in 1993. E.coli TS sequence shares 
46% identity with human TS, and its structure is almost identical to what has 
described above. Based on computer modelling of the crystallographically-
determined TS cofactor binding site, prototype inhibitors were synthesized. 
Next, their actual binding to the TS active site was determined by X-ray 
crystallography again, and used to refine the inhibitor structure [173]. After 
several rounds of refinement, researchers managed to derive tight binding 
molecule which was suitable for preclinical evaluation. Nolatrexed is a non-
glutamate-containing molecule which enters the cell by passive diffusion and 
does not undergo intracellular polyglutamylation. Nolatrexed is a potent TS 
inhibitor and displays broad range antitumor activities in vitro. Consistently, 
the cytotoxic effects can be antagonized by the addition of thymidine [168]. 
Two phase II clinical studies have generated very promising result for the use 
of nolatrexed in advanced HCC. However, phase III clinical trial comparing 
nolatrexed with doxorubicin failed to demonstrate the benefit of nolatrexed 
over doxorubicin in treatment of unresectable HCC. Hence the development of 






4.4 Development of novel FR-targeted antifolates  
The development of antifolate for cancer treatment started since the discovery 
of MTX in 1950s and continued for half a century. To date, there are only 
three major antifolates in the market, namely MTX, pemetrexed and 
raltitrexed. MTX is widely used to treat acute lymphoblastic leukemia, 
lymphoma and osteocarcinoma. Raltitrexed is used in Europe, Canada and 
Australia for advanced colorectal cancer and in several European countries for 
MPM. Pemetrexed was approved in US for treatment of MPM and NSCLC 
[81].  
Dozens of new antifolates have been invented but failed in the clinical trials. 
Toxicity accounts for many failures exampled by the cases of lometrexol and 
AG2034, which we have discussed in section 4.3.2. All the aforementioned 
antifolates are mainly transported by ubiquitously expressed RFC. As such, 
they have limited selectivity for tumor cells over normal proliferative tissues, 
which may contribute to the adverse effects. Given the high tumor to normal 
tissue expression of FRs, the interest and scope for the development of 
selective FR-targeted antifolate is large.  
The best example of FR-targeted therapy is the folate-conjugation system, 
which uses folic acid as a targeting agent. However, there are some potential 
complications associated with this approach. Firstly, the cytotoxic agent may 
be prematurely released before they reach the tumor cells,  resulting in toxicity 
to the normal cells. Secondly, after releasing the drug into the tumor cells, free 
folic acid may become a growth-sustaining nutrient, confounding the 





To combine the conventional antifolate and folate-conjugation system, a FR-
targeted antifolate is proposed, which is cytotoxic due to its inhibitory effects 
on nucleotides synthesis and is selectively uptaken by FRs.  
In this section, I will discuss two examples of FR-targeted antifolates and the 
structural basis for the recognition of conventional antifolates by FRs. 
4.4.1 Current effort in developing FR-targeted antifolates 
BGC945: Raltitrexed is the first TS inhibitor registered for anticancer 
chemotherapy. Its success prompted many groups to search for alternative 
inhibitors with better therapeutic value and less drug resistance. Raltitrexed 
relies on RFC for cellular entry. In addition, polyglutamylation dramatically 
increases its inhibitory potency to TS. As a result, drug resistance can arise 
from decreased RFC expression and /or impaired FPGS function. To 
overcome drug resistance, nolatrexed - a lipophilic TS inhibitor, which work 
independently of RFC or FPGS, has been designed by Agouron 
Pharmaceuticals.  
In contrast, a group from England took an alternative approach, replacing the 
glutamate moiety of raltitrexed with a variety of glutamate-derived ligands to 
find potent nonpolyglutamatable TS inhibitors. Since adding of a D-
enantiomer glutamate can prevent further glutamylation by FPGS and makes 
antifolate stable against hydrolysis, the glutamate moiety was replaced by an 
L-Glu-γ-D-Glu dipeptide, which reserves the H-bonds formed with TS. In 
addition, according to E.coli TS crystal structure, folate analogues bind in a 
partially folded conformation in which the aminobenzoyl group inclines 65° to 





pentacyclic ring connecting C7 and C9 will be favorable for binding to TS 
(Fig. 38).  Combining all of these modifications led to the development of the 
novel TS inhibitor-BGC945 [174]. 
BGC945 has low affinity for RFC; in contrast, it binds to FRα with a 70% 
affinity to folic acid. BGC945 is a potent TS inhibitor with Ki~1.2nM. 
Moreover, it displayed anti-tumor activity in a range of FRα positive human 
cancer cell lines. In the KB tumor-bearing mouse model, BGC945 was 
accumulated in the tumor tissue at a level that was ten times higher than in 
normal tissue [119]. These data suggest that BGC945 selectively inhibits TS in 
FRα-positive tumours with minimal toxicity to normal tissues. Currently, 
BGC945 is under phase I clinical trial launched by Onyx Pharmaceuticals to 
evaluate its safety and pharmacokinetics.  
 
Figure 38. Chemical structures of raltitrexed and BGC945.  
 
FR-targeted GARFT inhibitors: Based on the structure of pemetrexed, 







oxopyrrolo-pyrimidine antifolates differing only in the lengths of the carbon 
bridge (Fig. 39). They presented modest antitumor activity in leukemia cell 
line [175]. These compounds were later found to be inhibitors of GARFT with 
potent inhibitory activity against FR-expressing Chinese hamster ovary (CHO) 
cells and human tumor cells. Interestingly, these compounds were selectively 
transported into the cells through FRs instead of RFC [176]. Subsequently, 
researchers modified the compounds by isosteric replacement of  the pyrrolo 
ring with a thieno ring and generated a series of 6-substituted thieno-
pyrimidine antifolates (Fig. 39). These compounds have a high affinity to FRs 
at a level comparable to folic acid, and they are selectively cytotoxic to the 
cells expressing FRs but not RFC or PCFT [177]. This is the only FR-targeted 
GARFT inhibitor, and its antitumor efficacy and toxicity need to be further 
evaluated.  
 
Figure 39. Chemical structure of pemetrexed and two series of FR-











4.4.2 Structural insights of antifolate binding by FRs 
Aforementioned FR-targeted antifolates were designed using well-known 
antifolates as scaffolds. They were modified based on the knowledge of their 
target enzyme structures to ensure potency and selectivity. However, since the 
structure of FRs were unknown at that time, cell-based screening was required 
to identify the compounds with FR-dependent cytotoxicity.  
The recent findings unravelling the FR-antifolate complex structures have 
facilitated our understanding of the molecular determinants of antifolate 
binding. MTX, aminopterin and pemetrexed are classical antifolates which 
mimic the folic acid structure and contain glutamate moiety for 
polyglutamylation. The crystal structures of FRβ in complex with MTX, 
aminopterin and pemetrexed provide  atomic resolution models for FR-
targeted drug design [150]. 
Figure 40 shows the ligand binding pockets of the antifolates within FRβ. All 
of these antifolates bind to the receptor in the same orientation as folic acid, 
with the bicyclic ring buried inside and glutamate tail sticking outside. In 
addition, their ligand binding modes share many characteristics. Firstly, the 
bicyclic ring is stacked between the side chain of Y101 and W187. Secondly, 
although the exact path of ligand through the binding cleft differs, same 
hydrophobic residues line the middle part of the binding pocket (W118, W154, 
W156), which stabilize the benzoyl moiety of ligand by nonspecific 
hydrophobic interactions. Finally, the glutamate moiety is stabilized by several 
























Figure 40. Binding pockets of methotrexate, aminopterin and pemetrexed 
in FRβ. Antifolates are labelled as gray sticks, FRβ as green cartoon, residues 
in contact with ligand as green lines and H-bonds as yellow dashes. PDB code: 
FRβ-MTX: 4KN0; FRβ-aminopterin: 4KN1; FRβ-pemetrexed: 4KN2. 
     
three antifolates, whereas γ-carboxyl groups of aminopterin and MTX form 
additional H-bonds with Q116, which are absent in folic acid and pemetrexed 
binding. 
The major discrepancy in binding resides in the position and orientation of 
bicyclic rings of three antifolates. Strikingly, the diaminopteridine of 
aminopterin and methotrexate docks into the pocket as it is flipped 180° 
compared to folic acid. This is unexpected because the difference between the 
two bicyclic rings is very subtle. As a result, different sets of H-bonds were 
formed between FRβ and diaminopteridine although via same sets of residues 
(D97, R119, S190). In contrast, pyrollo-pyrimidine of pemetrexed sits in the 
binding cleft in the similar orientation as pterin of folic acid. Compared with 
pterin, pyrollo-pyrimidine rotates about 20° toward D97. As a result, the H-
bonds with S190 is lost and pemetrexed form a new H-bond with T98. All the 
other interactions in bicyclic ring are conserved.  
From structure analysis of FRα/β in complex with folic acid and antifolates, 
we concluded that to achieve high affinity binding with FRs, a compound 
should consist of an aromatic ring that can be stacked between Y85/Y101 and 
W171/W187 (residues in FRα/β respectively), a hydrophobic linker of an 
adequate length to travel through the binding pocket, and a glutamate moiety 
capable of forming polar interactions at the pocket entry. In addition, the 





here. Thus, a bulkier ligand which utilizes more space in the binding cleft can 
be synthesized and analyzed for increasing affinity.  
Armed with the structural knowledge of FRs and folate metabolic enzymes 
(DHFR, GARFT and TS), we are now at the frontline of the development of 
novel FR-targeted antifolates, which is specific to tumor overexpressing FRs 
and cytotoxic by inhibiting nucleotides synthesis. Structural studies of RFC 
and PCFT will be the way forward to provide critical information on how the 
transport of drugs to normal tissue via these two transporters can be minimized 






4.5 Conclusions and perspectives 
Folates are one-carbon donors that are required for the synthesis of nucleic 
acids. Rapidly dividing cells, such as cancer cells, are therefore much more 
dependent on folates than quiescent body cells. FRs are cell surface 
glycoproteins that mediate high affinity folate uptake through endocytosis. 
FRs are significantly expressed only in few cells, in particular cells important 
for embryonic development (e.g. placenta) and folate reabsorption (kidney), to 
allow selective folate uptake under folate-limiting conditions. A large 
proportion of tumors therefore hijack FR and express it at very high levels to 
meet their folate demand. High level expression of folate receptor is so cancer-
specific that it is hotly pursued as an anticancer drug target. 
In this study, we have overcome numerous technical barriers in the 
purification and crystallization of cysteine-rich glycoproteins and successfully 
solved the long awaited crystal structure of FRα bound to folic acid. This 
structure provided a detailed map of the extensive interaction network between 
folic acid and FRs, and rationalizes previous structure-activity relationship 
studies of several folate derivatives, including antifolates and folate conjugates. 
The information uncovered in this study paves the way for future structure-
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